

Preventing and Treating Childhood Mental Disorders: Effective Interventions

A Research Report

October 2020



Christine Schwartz
Donna Yung
Jen Barican
Charlotte Waddell

We celebrate the Indigenous Peoples on whose traditional territories we are all privileged to live and work.

Citing This Report

Schwartz, C., Yung, D., Barican, J., & Waddell, C. (2020). *Preventing and Treating Childhood Mental Disorders: Effective Interventions*. Vancouver, BC: Children's Health Policy Centre, Simon Fraser University.

Acknowledgements

The Child and Youth Mental Health Policy Branch of the British Columbia (BC) Ministry of Children and Family Development funded this project, with co-sponsorship from the BC Ministry of Mental Health and Addictions. We thank the Policy Advisory Committee for this project, who provided valuable input. We dedicate this report to BC's children. Our aim is to support them to flourish.

Children's Health Policy Centre

Faculty of Health Sciences, Simon Fraser University
2435 - 515 West Hastings Street, Vancouver, BC V6B 5K3
778.782.7775 | childhealthpolicy.ca

Contents

Executive Summary	4
1. Background	5
2. Methods	6
3. Findings on Effective Interventions	8
3.1 Anxiety Disorders.....	9
3.2 Attention-Deficit/Hyperactivity Disorder	10
3.3 Oppositional Defiant Disorder	11
3.4 Conduct Disorder	11
3.5 Substance Use Disorders	13
3.6 Depression.....	14
3.7 Autism Spectrum Disorder.....	15
3.8 Obsessive-Compulsive Disorder	16
3.9 Bipolar Disorder.....	16
3.10 Eating Disorders	17
3.11 Posttraumatic Stress Disorder	18
3.12 Schizophrenia	19
4. Conclusions	20
4.1 Prevention	20
4.2 Psychosocial Treatments	20
4.3 Medications	21
4.4 Moving Forward.....	22
References	23
Appendix: Study and Intervention Details	35

Executive Summary

Mental health, or social and emotional wellbeing, is a crucial resource for all children – enabling them to flourish, meet their potential and be resilient in the face of adversity. Yet based on high-quality epidemiological studies, an estimated 12.7% of children – or nearly 95,000 children aged four to 18 years in British Columbia – will experience mental disorders causing significant symptoms and impairment at any given time. All children with mental disorders require effective treatments, and many additional children would benefit from effective prevention programs.

To inform policymaking to address these needs, this report summarizes the best available research evidence on effective interventions for preventing and treating 12 of the most common mental disorders (or groups of disorders) affecting children aged 18 years or younger. These disorders include: 1) anxiety disorders; 2) attention-deficit/hyperactivity disorder (ADHD); 3) oppositional defiant and 4) conduct disorders; 5) substance use disorders (SUDs); 6) depression; 7) autism spectrum disorder; 8) obsessive-compulsive disorder (OCD); 9) bipolar disorder; 10) eating disorders; 11) posttraumatic stress disorder (PTSD); and 12) schizophrenia.

Our systematic review identified 113 randomized controlled trials (RCTs) and six systematic reviews that met inclusion criteria. Intervention effectiveness was defined as two or more RCT evaluations showing statistically-significant reductions in disorder diagnoses and/or symptoms for children. Applying these criteria, we identified effective prevention interventions for eight of the most common childhood mental disorders and effective treatments for all 12. However, estimates from high-quality epidemiological studies indicate that an estimated 55.8% of children with mental disorders – or nearly 53,000 children in BC – do not receive services for these disorders in a typical year. These estimates suggest stark service shortfalls, even apart from the question of effective services.

To address these high levels of need, a first step is adopting a comprehensive population health strategy for children’s mental health. Such a strategy includes:

- 1) Addressing social determinants and reducing avoidable childhood adversities that contribute to the development of mental health problems
- 2) Providing effective prevention programs, such as those reported here, for children at risk
- 3) Providing effective treatments, such as those reported here, for all children with disorders, and
- 4) Monitoring needs and outcomes over time to evaluate and improve intervention efforts.

Vigorous central leadership is also required to ensure that such a plan is sustained over time, accompanied by adequate and dedicated children’s mental health budgets, and coordinated across all relevant sectors within government. BC’s children will benefit, as will everyone, if children’s mental health is made a high public policy priority – and if children’s mental health needs are better met.

I. Background

I.1 The Importance of Children’s Mental Health

Mental health, or social and emotional wellbeing, is a crucial resource for all children in British Columbia (BC) – enabling them to flourish, meet their potential and be resilient in the face of adversity. For some children, however, development is interrupted by mental disorders. If not prevented or treated early, these disorders can lead to serious ongoing distress, symptoms and impairment for individual children, as well as distress and costs for their families – and substantial associated costs for society, particularly when disorders continue into adulthood.¹ An estimated 12.7% of children aged 18 years or younger (or 94,800 in BC) will meet the criteria for a mental disorder at any given time, including having both symptoms and impairment and therefore needing treatment.² Yet an estimated 55.8% of children with mental disorders (or 52,900 in BC) do not receive services for these disorders in a typical year.² Ensuring the timely availability of effective prevention and treatment interventions for all children in need is a crucial first step in addressing these service gaps. At the same time, policymakers require high-quality research evidence on such interventions to guide program planning and public investments.

**Mental health, or social and emotional wellbeing,
is a crucial resource for all children in British Columbia.**

I.2 Purpose of This Research Report

To inform policymaking in BC, this report summarizes the best available research evidence on effective interventions for preventing and treating 12 of the most common mental disorders occurring in children aged 18 years or younger. These disorders include: 1) anxiety disorders; 2) attention-deficit/hyperactivity disorder (ADHD); 3) oppositional defiant and 4) conduct disorders; 5) substance use disorders (SUDs); 6) depression; 7) autism spectrum disorder; 8) obsessive-compulsive disorder (OCD); 9) bipolar disorder; 10) eating disorders; 11) posttraumatic stress disorder (PTSD); and 12) schizophrenia.

Prevention interventions are programs that intervene before mental disorders develop. These programs typically aim to address underlying causes such as avoidable adversities that can lead to the development of mental disorders; they may be universal (offered to all children and/or families) or targeted (offered to those at risk). Meanwhile, treatment interventions include both psychosocial programs and medications.

The overarching goal is to assist in ensuring that all children in need in BC can access effective mental health interventions. The policy context is that of the BC Government’s ongoing commitment to enhancing children’s mental health services and to improving mental health outcomes for all children.

2. Methods

To compile the best available research evidence, we used systematic review methods adapted from the *Cochrane Collaboration* and *Evidence-Based Mental Health* to identify relevant randomized controlled trials (RCTs). We searched standard databases including Campbell, Cochrane, CINAHL, ERIC, Medline, PsycINFO and Web of Science for RCTs and/or systematic reviews. We built on work done for our previous peer-reviewed academic publications and our *Children's Mental Health Research Quarterly*. To ensure we included the most recent evidence, we conducted additional updating searches to identify new RCTs and systematic reviews for selected disorders where needed.

To be included, RCTs and systematic reviews had to be published in peer-reviewed journals. The interventions they assessed had to be delivered to children (aged 18 years or younger) and/or their families living in high-income countries (for comparability to BC). Study attrition had to be $\leq 20\%$ or intention-to-treat analyses had to be performed. For most RCTs, we required two or more informant sources (e.g., child, parent and/or teacher). Nevertheless, to ensure comprehensiveness we made exceptions for RCTs assessing psychosocial interventions aimed at preventing ADHD, preventing or treating SUDs and treating bipolar disorder because few included two or more sources.

For psychosocial intervention studies, we required at least one informant source to be “blinded.” In other words, child and/or family allocations to intervention or comparison groups were concealed from the assessors. The exceptions were RCTs on ADHD and PTSD prevention interventions and on psychosocial SUD interventions, because few included blinding. We also required follow-up of at least three months for all psychosocial interventions, with the exception of studies assessing OCD treatments because few tracked outcomes beyond the end of treatment.

For medication studies, we required double-blinding, that is, of both participants and assessors, as well as placebo controls and a comprehensive assessment of adverse events. The one exception was medications for schizophrenia, where we accepted studies directly comparing two medications without using a placebo, provided that one of the medications had already shown benefits in young people in a double-blind, placebo-controlled RCT. We excluded medications where the adverse events were particularly troubling and likely to outweigh potential benefits.

For disorders where research evidence was particularly abundant, we added criteria to ensure that we presented the best available evidence. For example, we required diagnostic outcomes for psychosocial prevention interventions for depression and required one-year follow-up for SUD prevention programs.

For all RCTs, we extracted outcomes for both diagnoses and core symptoms of the disorder, where possible. We classified measures of overall functioning as symptom measures. We reported outcomes at final follow-up, noting that RCTs vary considerably regarding this parameter. For example, most medication studies typically stopped at post-test, after children had been taking medications just several weeks, while many

psychosocial intervention studies followed children longer term, for months or years after the interventions ended.

For this report, for an intervention to be deemed effective, two or more RCTs conducted with children had to show statistically-significant reductions ($p < .05$) in disorder diagnoses and/or symptoms using reliable and valid measures. Throughout our process, all steps were conducted and verified by two or more team members, resolving any differences by consensus. The [Appendix](#) provides detailed information on our findings for each disorder.

This report is based on research evidence drawn from rigorous, high-quality studies evaluating intervention effectiveness, namely RCTs. RCTs are regarded as the best evidence for assessing the impact of health-related interventions.³⁻⁴ We nevertheless acknowledge that this methodology has limitations – including under-representing Indigenous Peoples as well as Indigenous Methods and perspectives.⁵⁻⁶

**We identified effective prevention interventions
for eight of the most common childhood mental disorders
and effective treatments for all twelve.**

3. Findings

We identified effective treatments for all 12 childhood disorders covered in this review – as well as effective prevention interventions for eight. Regarding treatment, for seven disorders (anxiety disorders, ADHD, oppositional defiant and conduct disorders, depression, OCD and bipolar disorder) both psychosocial interventions and medications met our inclusion criteria. For four disorders (SUDs, autism spectrum disorder, eating disorders and PTSD) only psychosocial interventions met criteria. For the remaining disorder (schizophrenia) only medications met criteria.

We have presented our findings based on prevalence, starting with the most common, namely anxiety disorders.² We have also provided estimates of the number of BC children affected by each disorder at any given time, based on applying prevalence data to Statistics Canada population data.⁷ (“Children” refer to those age 18 years or younger; “parent” refers to all individuals caring for children, including foster parents.)

We identified both universal and targeted prevention interventions. Universal prevention programs are delivered to entire populations, such as every student in a school, while targeted prevention programs are directed to children and families identified as being at risk, such as those experiencing disorder symptoms but not meeting full diagnostic criteria.

We have presented data on interventions for all anxiety disorders together because similar interventions were used for all. We have presented data on interventions for oppositional defiant and conduct disorders together for the same reason.

All effective interventions had at least two RCTs supporting their use with young people. For most disorders, we have presented data from the original RCTs. We have summarized these data in text, while also providing greater detail on the 113 RCTs that met our inclusion criteria in the [Appendix](#). We have also included RCT data contained in systematic reviews for the treatment of five disorders. We did this because most of these systematic reviews included meta-analyses providing additional information, such as relative efficacy or cost-effectiveness comparisons. Where possible, we have also provided information on the effect sizes of interventions. Effect sizes detail the degree of difference that the intervention made in children’s lives and help determine if intervention effects were clinically-meaningful.

**British Columbia’s children will benefit, as will everyone,
if children’s mental health is made a high public policy priority.**

3.1 Anxiety Disorders

Prevention

Four cognitive-behavioural therapy (CBT) interventions, evaluated in five RCTs, proved effective in preventing anxiety diagnoses and/or symptoms with children.⁸⁻¹³ One intervention was delivered universally while three were targeted. CBT typically involved educating children and families about anxiety, coaching children to reduce physical symptoms of anxiety using techniques such as deep breathing, teaching children to challenge unrealistic and unhelpful anxious thinking, and encouraging children to practice being in fear-provoking situations while managing their anxiety.¹⁴ (Because very similar CBT techniques are used for preventing and treating each anxiety disorder, we review all anxiety disorders together.)

Notably, CBT prevention programs were effective in a variety of formats including teaching parents to provide CBT to their young children, delivering CBT to groups of children or to individual families, or via self-delivery. CBT was effective at preventing anxiety symptoms across developmental periods with children from four to 17 years. In addition to all reported findings being statistically significant, CBT also showed large effect sizes. For example, one RCT found that the odds of being diagnosed with an anxiety disorder was more than eight times lower when young people received CBT.¹¹⁻¹²

Psychosocial Treatment

CBT also proved highly effective for treating anxiety disorders – with nine programs, assessed in 12 RCTs, significantly reducing the number of children with anxiety disorders and/or anxiety symptoms.¹⁵⁻²⁷ As with prevention, CBT was effective in a variety of formats including teaching parents to provide CBT to their young children, delivering CBT to children individually or in groups, or via self-delivery. Also similar to prevention, CBT was effective with children from two to 17 years. Where effect sizes were calculated, most were substantial. When young people received CBT, the odds of no longer meeting diagnostic criteria for any anxiety disorder was 2.5 to 8.5 times higher across three RCTs,^{18, 26-27} while the odds of no longer meeting criteria for their primary anxiety disorder was 3.7 to 4.9 times higher across two RCTs.^{25, 27}

Medications

Fluoxetine and sertraline effectively reduced anxiety symptoms in two RCTs each.²⁸⁻³¹ In one trial, fluoxetine also significantly reduced the number of children meeting criteria for their primary anxiety disorder.²⁸ One RCT calculated effects sizes, finding that young people prescribed sertraline had 3.9 times lower odds of continuing to have anxiety symptoms.³¹ However, both medications produced adverse events. Nausea and drowsiness were common for fluoxetine while drowsiness and dry mouth were common for sertraline.²⁹⁻³⁰

Table 1 summarizes the anxiety intervention findings as well as the prevalence for anxiety disorders and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the 21 RCTs evaluating anxiety interventions.

Table 1. Effective Anxiety Disorder Interventions

Anxiety Disorders	5.2% or 38,800 (4–18 years) in BC
Prevention: Cognitive-behavioural therapy (5 RCTs) ⁸⁻¹³	
Treatment (Psychosocial): Cognitive-behavioural therapy (12 RCTs) ¹⁵⁻²⁷	
Treatment (Medication): Fluoxetine (2 RCTs) ²⁸⁻²⁹ + sertraline (2 RCTs) ³⁰⁻³¹	

3.2 Attention-Deficit/Hyperactivity Disorder

Prevention

Three targeted parent training interventions, evaluated in four RCTs, proved effective in reducing symptoms of ADHD with at-risk children.³²⁻³⁸ (We use the phrase “parent training” because it the term commonly used in the research literature for programs focusing on teaching parents specific skills to help with children’s behavioural challenges.) Programs typically focused on teaching parents to encourage their child’s positive behaviour by providing attention and praise and by discouraging challenging behaviours, including ignoring minor misbehaviours.³⁹ All three programs focused on parents with young children, including one that began during pregnancy. As well, all were delivered in groups. The Incredible Years program stood out by reducing ADHD symptoms across two RCTs.³²⁻³³

Psychosocial Treatment

Three parent training programs also proved successful in reducing ADHD symptoms or diagnoses in three RCTs. These programs were effective in varying formats including delivery in groups, to individual parents and via self-delivery. The programs were also effective for children from three to 18 years.^{26, 40-41} The Strongest Families program stood out by reducing ADHD diagnoses. Specifically, the odds of children continuing to have an ADHD diagnosis five months after their parents completed the program was 2.7 times lower.²⁶

As well, two multicomponent interventions reduced ADHD symptoms with school age children.⁴²⁻⁴³ Both combined parent training with child behaviour therapy and child social skills training. Behaviour therapy involved rewarding children for positive behaviours, while social skills training involved teaching children strategies to improve relationships including taking turns and sharing.⁴³

Medications

Methylphenidate, dextroamphetamine and atomoxetine were effective in significantly reducing ADHD symptoms based on a meta-analysis of 64 RCTs.⁴⁴ A cost-effectiveness analysis favoured methylphenidate and dextroamphetamine given that they were less expensive while being as effective as atomoxetine. However, all medications produced adverse events, including decreased appetite, insomnia and stomach-aches, without significant differences between them. Another meta-analysis of 26 RCTs found that methylphenidate used alone or in combination with psychosocial treatments was significantly more effective than psychosocial treatments alone.⁴⁵

Table 2 summarizes the ADHD findings as well as the prevalence for ADHD and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the 11 RCTs and the two meta-analyses evaluating the ADHD interventions.

Table 2. Effective ADHD Interventions

ADHD	3.7% or 27,600 (4–18 years) in BC
Prevention: Parent training (4 RCTs) ^{32–38}	
Treatment (Psychosocial): Parent training (3 RCTs) ^{26, 40–41} + multicomponent interventions (2 RCTs in total) ^{42–43} with each including behaviour therapy, parent training + social skills training	
Treatment (Medication): Methylphenidate, dextroamphetamine + atomoxetine (2 meta-analyses including 78 RCTs) ^{44–45}	

3.3 Oppositional Defiant and 3.4 Conduct Disorders

Prevention

Six parent training programs, evaluated in 10 RCTs, proved effective in preventing symptoms of oppositional defiant and conduct disorders – when delivered universally and to at-risk children.^{46–58} Programs typically focused on teaching parents to encourage their child’s positive behaviour by providing attention and praise and managing challenging behaviours, including by ignoring minor misbehaviours.⁵⁹ These parent training programs were delivered both in groups and individually, including using self-directed formats. While most participating parents had young children, typically preschool age, Nurse-Family Partnership began prenatally while Parent-Management Training included parents of children up to age 10. Among these programs, Triple P and Incredible Years stood out by showing success across multiple RCTs.^{46, 48, 51–52, 57–58}

Five other programs, evaluated in five RCTs, also proved successful in reducing diagnosis and/or symptoms – by using either single interventions or multicomponent interventions. These included combinations of parent training, behaviour therapy, social skills training, enriched school curricula, and/or parent-school collaborations.^{60–65} Behaviour therapy involved rewarding children for their positive behaviours while social

skills training taught children strategies to improve their relationships.⁶² The enriched school curricula focused on building children’s skills to promote school success, including self-control and critical thinking, while parent-school collaborations aimed to increase communication between parents and teachers.⁶² Notably, all five programs were delivered in educational settings, beginning in grade one or earlier. Two programs – Good Behavior Game and Fast Track – stood out by showing very long-term success, including reducing antisocial personality disorder diagnoses in adulthood up to 14 years after the programs ended.^{60,63}

Psychosocial Treatment

Two parent training interventions, evaluated in two RCTs, successfully reduced symptoms of behaviour disorders in young children.⁶⁶⁻⁶⁸ For example, children whose parents who participated in Incredible Years had five times higher odds of *not* meeting diagnostic criteria for oppositional defiant disorder nearly eight years after the study ended, compared with children of parents who did not participate in the program.⁶⁶ As well, three youth-oriented interventions showed success in four RCTs.⁶⁹⁻⁷² One used cognitive-behavioural therapy (CBT) to teach young people strategies for coping and solving problems.⁶⁹ The two other programs used parent training and youth social skills training or CBT, delivering parent and youth components separately, as well as in family sessions.⁷⁰⁻⁷³

Medications

Risperidone reduced behaviour symptoms according to three RCTs.⁷⁴⁻⁷⁶ However, adverse effects, including fatigue and weight gain, were frequent.⁷⁴⁻⁷⁶

Table 3 summarizes the intervention findings as well as the prevalence for oppositional defiant and conduct disorders and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the 23 RCTs evaluating the oppositional defiant and conduct disorder interventions.

Table 3. Effective Oppositional Defiant and Conduct Disorder Interventions

Oppositional Defiant Disorder	3.3% or 24,600 (4–18 years) in BC
Conduct Disorder	1.3% or 9,700 (4–18 years) in BC
<p>Prevention: Parent training (10 RCTs)⁴⁶⁻⁵⁸ + multicomponent interventions (5 RCTs in total with 1 RCT evaluating a single component)⁶⁰⁻⁶⁵ including combinations of behaviour therapy, enriched school curricula, parent-school collaborations, parent training +/- or social skills training.</p> <p>Treatment (Psychosocial): Parent training (2 RCTs)⁶⁶⁻⁶⁸ + multicomponent interventions (4 RCTs in total with 1 RCT evaluating a single component)⁶⁹⁻⁷³ including combinations of cognitive-behavioural therapy, parent training +/- or social skills training</p> <p>Treatment (Medication): Risperidone (3 RCTs)⁷⁴⁻⁷⁶</p>	

3.5 Substance Use Disorders

Prevention

Six universal programs, evaluated in six RCTs, proved effective in reducing substance use. All were multicomponent interventions including combinations of resistance skills, parent training, child education, child social skills training, and child-and-family communication skills training.⁷⁷⁻⁸⁶ Resistance skills focused on teaching young people to strategies to withstand peer pressure.⁸⁷ Parent training focused on enhancing skills including setting limits, rewarding adaptive behaviours and providing consequences for children's substance use.^{84,88} Child education involved teaching young people about the effects of substance use and correcting misbeliefs.⁸⁵ Child social skills training included teaching young people skills for establishing and maintaining positive peer relationships.⁸⁸ Communication skills training focused on improving dialogues between children and parents.^{84,89} Five programs were delivered to groups of children in schools, typically between grades six and nine, while one program used self-directed delivery with daughters and mothers.⁸⁴ Among the six programs, Unplugged stood out by showing success in two RCTs, with comparison youth having 1.3 times greater odds of drunkenness and 1.8 times greater odds of cannabis use in the past month.⁸⁵⁻⁸⁶

Three targeted prevention programs, evaluated in four RCTs, also proved effective in reducing substance use using either a single intervention or a multicomponent intervention.^{88,90-94} These interventions included motivational interviewing, cognitive-behavioural therapy (CBT), social skills training and education. Motivational interviewing included encouraging young people to examine the negative consequences of substance use as well as potential benefits for reducing it.⁹⁵ CBT included examining triggers for substance use, challenging beliefs that supported substance use and learning to avoid high risk situations. Of the three programs, two were delivered in groups and one was delivered individually – with young people who ranged from 10 to 18 years. The Preventure program – which was delivered in schools – stood out by showing success in two RCTs.^{92,94} As well, its effect size was moderately high, with one RCT showing that comparison youth had 1.4 times greater odds of showing symptoms of problematic alcohol use.

Psychosocial Treatment

Four programs, evaluated in six RCTs, proved effective in reducing substance use with young people who had a substance use disorder by using either a single intervention or a multicomponent intervention. These interventions included parent training, family communication skills, CBT, social skills training and motivational interviewing.⁹⁶⁻¹⁰¹ Family communication skills focused on teaching parents and children effective ways to engage with each other.¹⁰⁰ Three programs were delivered to either young people or their families, while one provided individual family sessions and a group for youth.⁹⁸ Of these four programs, Multidimensional Family Therapy stood out by showing positive outcomes in three RCTs, including one where participating teens had more than double of the odds of abstaining from substance use.¹⁰¹

Table 4 summarizes the main substance use findings as well as the prevalence for SUDs and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the 16 RCTs evaluating substance use disorder interventions.

Table 4. Effective Substance Use Disorder Interventions

Substance Use Disorders	2.3% or 8,200 (12–18 years) in BC
<p>Prevention: Multicomponent interventions (10 RCTs in total with 1 RCT evaluating a single component)^{77–95} including combinations of child education, cognitive-behavioural therapy, communication skills, motivational interviewing, parent training, resistance skills, +/- social skills training</p> <p>Treatment (Psychosocial): Multicomponent interventions (6 RCTs in total with 1 RCT evaluating a single component)^{96–101} including combinations of cognitive-behavioural therapy, family communication skills, motivational interviewing, parent training +/- social skills training</p>	

3.6 Depression

Prevention

Four targeted cognitive-behavioural therapy (CBT) interventions, evaluated in six RCTs, proved effective in reducing depression diagnoses and/or symptoms.^{102–108} CBT typically involved educating children and families about depression, teaching children to challenge unrealistic and unhelpful thinking, and encouraging children to engage in more pleasurable and productive activities.¹⁰⁹ All CBT programs were delivered in groups, two provided to children and one to families. The remaining CBT intervention was a book that youth read. These interventions were completed by young people ranging in age from nine to 19 years. The program Coping with Stress stood out by showing positive outcomes across four RCTs, including three that reduced depression diagnoses. Effect sizes were also impressive. For example, in one RCT, two years after completing Coping with Stress, youth had 60% reductions in major depressive disorder diagnoses.¹⁰⁶

Psychosocial Treatment

A meta-analysis of 52 RCTs found that interpersonal therapy (IPT) and CBT effectively reduced depression symptoms in children.¹¹⁰ IPT focused on helping young people make connections between depressive symptoms and specific problems such as grief and role transitions, and supporting them to develop strategies for addressing these problems.¹¹¹ Both IPT and CBT were more effective than treatment-as-usual, waitlist controls and play therapy at the end of treatment. However, at six- to 12-month follow-up, only IPT was more effective than treatment-as-usual. IPT was also more effective than CBT at follow-up.¹¹⁰

Medications

Fluoxetine effectively reduced mood symptoms for children and youth across four RCTs.^{112–115} However, fluoxetine also produced adverse events including significantly more “suicide-related events” (such as

attempts and suicidal thoughts)¹¹⁶ and headaches than placebo.¹¹⁴

Table 5 summarizes the main depression findings as well as the prevalence for depression and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the 10 RCTs and the meta-analysis evaluating the depression interventions.

Table 5. Effective Depression Interventions

Depression	1.3% or 9,700 (4–18 years) in BC
Prevention: Cognitive-behavioural therapy (6 RCTs) ^{102–108}	
Treatment (Psychosocial): Interpersonal therapy + cognitive-behavioural therapy (meta-analysis including 52 RCTs) ¹¹⁰	
Treatment (Medication): Fluoxetine (4 RCTs) ^{112–115}	

3.7 Autism Spectrum Disorder

Psychosocial Treatment

Six behavioural and two cognitive-behavioural therapy (CBT) interventions improved core symptoms of autism spectrum disorder according to a systematic review of eight RCTs.¹¹⁷ The behavioural interventions focused on increasing children’s appropriate engagement in social interactions^{118–123} while CBT taught children skills including taking others’ perspective and adapting their behaviour to different situations.^{124–125} Most behavioural interventions involved teaching individual parents skills to use with their children. The exception was a computer program for children.¹²³ In comparison, both CBT interventions were delivered to groups of children. All interventions focused on younger children, with behavioural interventions typically focused on preschoolers and CBT focused on school-age children.

Table 6 summarizes the main autism findings as well as the prevalence for autism spectrum disorder and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the systematic review that reported the RCTs.

Table 6. Effective Autism Spectrum Disorder Interventions

Autism Spectrum Disorder	0.4% or 3,000 (4–18 years) in BC
Treatment (Psychosocial): Behavioural + cognitive-behavioural therapy (1 systematic review including 8 relevant RCTs) ¹¹⁷	

3.8 Obsessive-Compulsive Disorder

Psychosocial Treatment

Nine cognitive-behavioural therapy (CBT) interventions proved effective in reducing OCD diagnoses and/or symptoms.¹²⁶⁻¹³⁴ CBT typically began by providing children and parents with information about OCD, then teaching children anxiety management strategies – such as breathing and relaxation techniques – as well as how to challenge unrealistic and unhelpful anxious thinking. Children were also supported to confront their obsessions while resisting the urge to engage in compulsions.¹³⁵ CBT was effective whether it was delivered to individual children or individual families, including a version that families completed over the internet with only minimal support from a practitioner. CBT was also effective with children between three and 18 years.

Medications

Fluoxetine, sertraline, paroxetine and clomipramine proved effective in reducing OCD symptoms based on a meta-analysis of 13 RCTs.¹³⁶ Fluoxetine stood out by showing effectiveness in three RCTs and by having a more favourable adverse event profile. In contrast, clomipramine was associated with particularly concerning adverse events including serious heart rhythm abnormalities.¹³⁷ But notably, when compared, CBT produced significantly larger treatment effects than any of the medications.¹³⁶

Table 7 summarizes the main OCD findings as well as the prevalence for OCD and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the nine RCTs and one meta-analysis evaluating the OCD interventions.

Table 7. Effective OCD Interventions

OCD	0.3% or 2,200 (4–18 years) in BC
Treatment (Psychosocial): Cognitive-behavioural therapy (9 RCTs) ¹²⁶⁻¹³⁴	
Treatment (Medication): Fluoxetine, sertraline, paroxetine + clomipramine (1 meta-analysis including on 3 RCTs for fluoxetine + 2 RCTs for all other medications) ¹³⁶	

3.9 Bipolar Disorder

Psychosocial Treatment

Three multicomponent interventions proved effective in reducing symptoms of bipolar disorder across four RCTs.¹³⁸⁻¹⁴¹ These interventions included family education, problem-solving and communication training. Family education included providing information about bipolar disorder while problem-solving focused on identifying problems, brainstorming solutions, then implementing the best of these. Communication training involved teaching skills to families including listening actively and providing effective feedback.^{138, 141}

Importantly, most young people were also taking medications for their bipolar disorder. Two interventions were delivered to individual families while the third was delivered to children and parents in separate groups.

Medications

Lithium was effective in reducing bipolar disorder symptoms according to two RCTs.¹⁴²⁻¹⁴³ However, it was associated with adverse events including excessive thirst, nausea, vomiting, headache and tremor, among others.¹⁴²⁻¹⁴³

Table 8 summarizes the main bipolar findings as well as the prevalence for bipolar disorder and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the six RCTs evaluating the bipolar interventions.

Table 8. Effective Bipolar Disorder Interventions

Bipolar Disorder	0.3% or 1,100 (12–18 years) in BC
Treatment (Psychosocial): Multicomponent interventions including combinations of communication skills, family education + problem-solving (adjunctive to medications in most cases) (4 RCTs) ¹³⁸⁻¹⁴¹	
Treatment (Medication): Lithium (2 RCTs) ¹⁴²⁻¹⁴³	

3.10 Eating Disorders

Prevention

Four multicomponent interventions, evaluated in five RCTs, proved effective in reducing symptoms of eating disorders, including one universal program and three that were targeted.¹⁴⁴⁻¹⁵⁰ Program components included discouraging unhealthy weight control practices, such as dieting, and encouraging positive body image using strategies such as challenging negative thoughts that young people had about their bodies.^{146-147, 150} Additional components included media literacy training – which involved developing skills to address an overemphasis on thinness – and implementing a healthy lifestyle plan, including changes to food intake and activity levels.^{144, 149-150} Three programs were delivered to groups of girls, while one was self-directed and included both boys and girls. The universal program stood out by reducing bulimia diagnoses.¹⁴⁴

Psychosocial Treatment

Family therapy resulted in significantly more young people achieving remission from anorexia nervosa at follow-up compared with individual child therapy, based on a meta-analysis of three RCTs.¹⁵¹ Family therapy focused on helping parents avoid blaming themselves for their child’s eating disorder and helping the family develop a plan for restoring the child’s weight through eating meals together – until the child was able to take more control over their own eating.¹⁵²⁻¹⁵³ Family therapy also resulted in significantly more

young people achieving remission from bulimia nervosa at follow-up compared with individual child therapy, based on two RCTs covered in the same meta-analysis.¹⁵¹ Family therapy for bulimia nervosa emphasized parental management of children’s eating behaviours.¹⁵⁴

Table 9 summarizes the eating disorder findings as well as the prevalence for eating disorders and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the five RCTs and one meta-analysis evaluating the eating disorder interventions.

Table 9. Effective Eating Disorder Interventions

Eating Disorders	0.2% or 700 (12–18 years) in BC
<p>Prevention: Multicomponent interventions (5 RCTs in total)^{144–150} including combinations of discouraging unhealthy weight control practices, encouraging positive body image, implementing healthy lifestyle plan +/- media literacy training</p> <p>Treatment (Psychosocial): Family therapy (1 meta-analysis including 5 RCTs)¹⁵¹</p>	

3.1.1 Posttraumatic Stress Disorder

Prevention

Four targeted cognitive-behavioural therapy (CBT) interventions, evaluated in five RCTs, proved effective in reducing posttraumatic stress symptoms in children who had been maltreated.^{155–160} CBT typically involved teaching children specific skills including recognizing emotions, solving problems and managing anger.¹⁵⁵ Importantly, parents were involved in three of the programs, including being taught ways to support their children and improve communications with them.^{158–160} Two interventions were delivered in groups and two delivered to individual families. Participating children ranged from six to 17 years.

Psychosocial Treatment

Three CBT interventions proved successful in reducing posttraumatic stress disorder (PTSD) symptoms and/or diagnoses.^{161–163} One reduced PTSD diagnoses and symptoms in girls who had been sexually abused.¹⁶² The other two reduced symptoms for children exposed to a variety of traumas.^{161, 163} These CBT interventions typically included educating children about common reactions to trauma, teaching breathing exercises, and helping children to recount their traumatic experiences while being supported.^{161–162} Two interventions were delivered to individual children while one was delivered in groups. Participating children ranged from seven to 18 years.

Table 10 summarizes the main PTSD findings as well as the prevalence for PTSD and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the eight RCTs evaluating the PTSD interventions.

Table 10. Effective PTSD Interventions

PTSD	0.1% or 700 (4–18 years) in BC
Prevention: Cognitive-behavioural therapy (5 RCTs, 2 of which also included parent training) ^{144–150}	
Treatment (Psychosocial): Cognitive-behavioural therapy (3 RCTs) ^{161–163}	

3.12 Schizophrenia

Medications

Aripiprazole and olanzapine were both effective in reducing schizophrenia symptoms according to two RCTs each.^{164–167} However, these medications were associated with adverse events. Sedation and tremors were common with aripiprazole, while elevated prolactin levels and weight gain were common with olanzapine.^{165–166}

Table 11 summarizes the schizophrenia findings well as the prevalence for schizophrenia and the estimated number of BC children affected at any given time. The [Appendix](#) gives more details on the four RCTs evaluating these medications.

Table 11. Effective Schizophrenia Interventions

Schizophrenia	0.1% or 400 (12–18 years) in BC
Treatment (Medication): Aripiprazole (2 RCTs) ^{164–165} + olanzapine (2 RCTs) ^{166–167}	

Psychosocial interventions can be cost-effective,
in addition to being clinically effective.

4. Conclusions

4.1 Prevention

We found effective prevention interventions for eight of the 12 most common childhood mental disorders including anxiety disorders, ADHD, oppositional defiant and conduct disorders, SUDs, depression, eating disorders and PTSD. These findings show that there are numerous opportunities to protect children from the unnecessary distress and impairment caused by these disorders. Still, despite strong evidence for prevention, these kinds of programs receive limited funding in most jurisdictions. In Canada, public health spending has constituted only 5.4% of health expenditures overall.¹⁶⁸ This suggests there are considerable opportunities for further investments in prevention. BC has shown leadership in this area, including making significant investments in three prevention programs identified in this review. This includes developing CBT resources for teachers, school counsellors and parents to support children with anxiety.¹⁶⁹ BC has also invested in Parent Management Training – Oregon, adapted for local use, called Confident Parents: Thriving Kids.¹⁶⁹ Finally, Nurse Family Partnership is being evaluated through the BC Healthy Connections Project¹⁷⁰⁻¹⁷¹ and is being provided as an enhanced public health service to young first-time mothers and their children in four regional health authorities.¹⁷²

Prevention investments also confer benefits to society as a whole through averted “downstream” costs in the healthcare, special education, child protection and justice systems – as well as reducing economic losses associated with people’s societal contributions when disorders persist unnecessarily into adulthood.¹⁷³⁻¹⁷⁴ For example, preventing a single case of conduct disorder has been estimated to yield lifetime savings of \$5–8 million per child.¹⁷⁵ (All figures reflect 2020 CAD values.) Regarding the prevention of behaviour disorders more generally, economic returns have been estimated for five successful programs covered in this review. Most calculations involve net benefit estimations, which account for both program delivery costs and long-term saving across multiple public service sectors – both for participants and for society – such as savings resulting from reductions in crime.¹⁷⁴ Using this approach, Incredible Years produced returns of approximately \$9 thousand per child.¹⁷⁶ Similarly, the Good Behaviour Game led to net benefits of approximately \$14 thousand per child¹⁷⁶ while Nurse-Family Partnership and Parent Management Training led to net benefits of \$6 thousand and \$8 thousand per child, respectively.¹⁷⁶ The estimated benefits of Perry Preschool were calculated using a different metric, with estimated returns of approximately \$10–23 dollars for every dollar invested.¹⁷⁷ In other words, as well as effectively preventing disorders and/or symptoms from arising, these successful programs may pay for themselves by reducing the use of other public services over time.¹⁷⁶

4.2 Psychosocial Treatments

We found effective psychosocial treatments for 11 of the 12 mental disorders covered in this review including anxiety, ADHD, oppositional defiant and conduct disorders, SUDs, depression, autism, OCD, bipolar disorder, eating disorders and PTSD. Notably, many effective treatments resulted in children

experiencing benefits beyond symptom reductions – including disorder remission. As well, gains were often enduring, with 15 interventions – evaluated in 17 RCTs – showing benefits persisting for a year or more post-treatment. Also, many treatments were delivered efficiently, in group and self-directed formats, allowing more children to be reached.

Several psychosocial treatments had particularly strong evidence of effectiveness, including multiple RCTs showing beneficial outcomes and large effect sizes, warranting their use as a first-line treatment. These include: CBT for anxiety, PTSD and OCD; parent training for oppositional defiant and conduct disorders; IPT for depression; behavioural interventions for autism spectrum disorder; and family therapy for eating disorders. Parent training also has evidence of success in helping youth with SUDs as well as helping children with ADHD, particularly when combined with an effective medication. Similarly, problem-solving and communication skills training may be helpful adjunctively to medication for young people with bipolar disorder.

Psychosocial interventions can be cost-effective, in addition to being clinically effective. This has been demonstrated through net benefit calculations which account for both program delivery costs and long-term saving across multiple public service sectors – for participants and for society. According to estimates from such economic evaluations, CBT for childhood anxiety disorders produced a net benefit of approximately \$14 thousand per child.¹⁷⁶ (All figures reflect 2020 CAD values.) Similarly, CBT for childhood OCD produced a net benefit of nearly \$16 thousand per child.¹⁷⁶ Parent training for ADHD produced a net benefit of slightly more than \$12 thousand per child.¹⁷⁶ As well, two programs for oppositional defiant and conduct disorders – Multidimensional Treatment Foster Care and Multisystemic Therapy – showed net benefits of approximately \$43 and \$24 thousand per child respectively.¹⁷⁶ As well as effectively treating children’s symptoms, impairment and distress, these programs may therefore also pay for themselves by reducing the use of other public services over time.

4.3 Medications

Medications showed success in treating eight of the 12 disorders covered in this review including anxiety, ADHD, oppositional defiant and conduct disorders, depression, OCD, bipolar disorder and schizophrenia. However, there is strong evidence that psychosocial interventions alone can suffice for effectively treating anxiety, oppositional defiant and conduct disorders, depression and OCD. Psychosocial interventions should therefore be offered first for these disorders – and medications only considered after psychosocial interventions have been maximized, particularly considering medication side effects. For example, while risperidone may reduce symptoms of oppositional defiant and conduct disorders, it can lead to serious cardiovascular and endocrine adverse events.¹³⁷ As well, medications for these disorders do not yield the same long-term gains that psychosocial interventions do.

Even for conditions where medications are considered a first-line treatment – such as ADHD, bipolar disorder and schizophrenia – risks and benefits must still be carefully weighed. For example, longer-term use of methylphenidate and dextroamphetamine has been associated with decreases in children’s height

and weight.¹⁷⁸ As well, while lithium can address bipolar symptoms, it can also cause renal and endocrine problems, among other difficulties, and consequently requires ongoing monitoring.¹⁷⁹ Similarly, while aripiprazole and olanzapine can address schizophrenia symptoms, both require careful oversight to ensure that cardiovascular and other side effects are managed.

There is also a clear need to evaluate medications that are being prescribed to young people – but where high-quality studies are lacking.¹⁸⁰ For example, young people with opioid use disorders are sometimes prescribed suboxone or methadone, even though these drugs have yet to be rigorously evaluated for use in youth.¹⁸¹

4.4 Moving Forward

Mental disorders typically start in childhood and cause significant impairment and distress – interfering with development and preventing children from flourishing and reaching their potential.¹⁸² Beyond the hardships that these disorders cause for individual children and families, there are also significant avoidable costs for society as a whole.¹⁷⁶ Adding to the burdens, without effective prevention or treatment interventions early in life, mental disorders often persist into adulthood, causing distress and avoidable costs over the lifespan.¹⁸³⁻¹⁸⁴

Based on 113 randomized controlled trials (RCTs) and six systematic reviews, we identified effective prevention interventions for eight of the most common childhood mental disorders and effective treatments for all 12. However, estimates from high-quality epidemiological studies indicate that an estimated 55.8% of children with mental disorders – or nearly 53,000 children in BC – do not receive services for these disorders in a typical year.² These estimates suggest stark service shortfalls, even apart from the question of effective services.

To address these high levels of need, a first step is adopting a comprehensive population health strategy for children’s mental health. Such a strategy includes:

- 1) Addressing social determinants and reducing avoidable childhood adversities that contribute to the development of mental health problems
- 2) Providing effective prevention programs, such as those reported here, for children at risk
- 3) Providing effective treatments, such as those reported here, for all children with disorders, and
- 4) Monitoring needs and outcomes over time to evaluate and improve intervention efforts.

Vigorous central leadership is also required to ensure that such a plan is sustained over time, accompanied by adequate and dedicated children’s mental health budgets, and coordinated across all relevant sectors within government. BC’s children will benefit, as will everyone, if children’s mental health is made a high public policy priority – and if children’s mental health needs are better met.

References

1. Waddell, C., Schwartz, C., & Andres, C. (2017). Making children's mental health a public policy priority: For the one and the many. *Public Health Ethics*, *11*, 1-10.
2. Barican, J., Yung, D., Zheng, Y., Schwartz, C., Georgiades, K., & Waddell, C. (2020). Prevalence of children's mental disorders: A systematic review and meta-analysis to inform policy. Manuscript in preparation.
3. Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M. J., & Welch, V. A. (Eds.). (2019). *Cochrane Handbook for Systematic Reviews of Interventions version 6.0* (updated July 2019). Retrieved September 2020, from www.training.cochrane.org/handbook
4. Hariton, E., & Locascio, J. J. (2018). Randomised controlled trials – the gold standard for effectiveness research. *British Journal of Obstetrics and Gynaecology*, *125*, 1716.
5. Saini, M., & Quinn, A. (2013). *A systematic review of randomized controlled trials of health related issues with an Aboriginal context*. Prince George, BC: National Collaborating Centre for Aboriginal Health.
6. Glover, M., Kira, A., Johnston, V., Walker, N., Thomas, D., Chang, A. B., . . . Brown, N. (2015). A systematic review of barriers and facilitators to participation in randomized controlled trials by Indigenous people from New Zealand, Australia, Canada, and the United States. *Global Health Promotion*, *22*, 21-31.
7. Statistics Canada. (2020). *Table 17-10-0134-01 Estimates of population (2016 Census and administrative data), by age groups and sex for July 1st, Canada, provinces, territories, health regions (2018 boundaries) and peer groups*. Retrieved August 2020, from <https://doi.org/10.25318/1710013401-eng>
8. Calar, A. L., Christensen, H., Mackinnon, A., Griffiths, K. M., & O'Kearney, R. (2009). The YouthMood Project: A cluster randomized controlled trial of an online cognitive behavioral program with adolescents. *Journal of Consulting and Clinical Psychology*, *77*, 1021-1032.
9. Bayer, J. K., Beatson, R., Bretherton, L., Hiscock, H., Wake, M., Gilbertson, T., . . . Rapee, R. M. (2018). Translational delivery of Cool Little Kids to prevent child internalising problems: Randomised controlled trial. *Australian and New Zealand Journal of Psychiatry*, *52*, 181-191.
10. Ginsburg, G. S. (2009). The Child Anxiety Prevention Study: Intervention model and primary outcomes. *Journal of Consulting and Clinical Psychology*, *77*, 580-587.
11. Ginsburg, G. S., Drake, K. L., Tein, J. Y., Teetsel, R., & Riddle, M. A. (2015). Preventing onset of anxiety disorders in offspring of anxious parents: A randomized controlled trial of a family-based intervention. *American Journal of Psychiatry*, *172*, 1207-1214.
12. Pella, J. E., Drake, K. L., Tein, J. Y., & Ginsburg, G. S. (2017). Child Anxiety Prevention Study: Impact on functional outcomes. *Child Psychiatry & Human Development*, *48*, 400-410.
13. Hunt, C., Andrews, G., Crino, R., Erskine, A., & Sakashita, C. (2009). Randomized controlled trial of an early intervention programme for adolescent anxiety disorders. *Australian & New Zealand Journal of Psychiatry*, *43*, 300-304.
14. Schwartz, C., Waddell, C., Barican, J., Andres, C., Yung, D., & Gray-Grant, D. (2016). Helping children with anxiety. *Children's Mental Health Research Quarterly*, *10*, 1-16. Vancouver, BC: Children's Health Policy Centre, Faculty of Health Sciences, Simon Fraser University.
15. Hudson, J. L., Rapee, R. M., Deveney, C., Schniering, C. A., Lyneham, H. J., & Bovopoulos, N. (2009). Cognitive-behavioral treatment versus an active control for children and adolescents with anxiety disorders: A randomized trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *48*, 533-544.
16. Lau, E. X., Rapee, R. M., & Coplan, R. J. (2017). Combining child social skills training with a parent early intervention program for inhibited preschool children. *Journal of Anxiety Disorders*, *51*, 32-38.

17. Kendall, P. C., Hudson, J. L., Gosch, E., Flannery-Schroeder, E., & Suveg, C. (2008). Cognitive-behavioral therapy for anxiety disorder in youth: A randomized clinical trial evaluating child and family modalities. *Journal of Consulting & Clinical Psychology, 76*, 282–297.
18. Silk, J. S., Tan, P. Z., Ladouceur, C. D., Meller, S., Siegle, G. J., McMakin, D. L., . . . Ryan, N. D. (2018). A randomized clinical trial comparing individual cognitive behavioral therapy and child-centered therapy for child anxiety disorders. *Journal of Clinical Child & Adolescent Psychology, 47*, 542–554.
19. Dadds, M. R., Holland, D. E., Laurens, K. R., Mullins, M., Barrett, P. M., & Spence, S. H. (1999). Early intervention and prevention of anxiety disorders in children: Results at 2-year follow-up. *Journal of Consulting and Clinical Psychology, 67*, 145–150.
20. Bernstein, G. A., Bernat, D. H., Victor, A. M., & Layne, A. E. (2008). School-based interventions for anxious children: 3-, 6-, and 12-month follow-ups. *Journal of the American Academy of Child & Adolescent Psychiatry, 47*, 1039–1047.
21. Lee, S. S., Victor, A. M., James, M. G., Roach, L. E., & Bernstein, G. A. (2016). School-based interventions for anxious children: Long-term follow-up. *Child Psychiatry & Human Development, 47*, 183–193.
22. Ollendick, T. H., Ost, L. G., Reuterskiold, L., Costa, N., Cederlund, R., Sirbu, C., . . . Jarrett, M. A. (2009). One-session treatment of specific phobias in youth: A randomized clinical trial in the United States and Sweden. *Journal of Consulting & Clinical Psychology, 77*, 504–516.
23. Rapee, R. M., Kennedy, S. J., Ingram, M., Edwards, S. L., & Sweeney, L. (2010). Altering the trajectory of anxiety in at-risk young children. *American Journal of Psychiatry, 167*, 1518–1525.
24. Masia-Warner, C., Fisher, P. H., Shrout, P. E., Rathor, S., & Klein, R. G. (2007). Treating adolescents with social anxiety disorder in school: An attention control trial. *Journal of Child Psychology & Psychiatry & Allied Disciplines, 48*, 676–686.
25. Masia-Warner, C., Colognori, D., Brice, C., Herzig, K., Mufson, L., Lynch, C., . . . Klein, R. G. (2016). Can school counselors deliver cognitive-behavioral treatment for social anxiety effectively? A randomized controlled trial. *Journal of Child Psychology & Psychiatry & Allied Disciplines, 57*, 1229–1238.
26. McGrath, P. J., Lingley-Pottie, P., Thurston, C., MacLean, C., Cunningham, C., Waschbusch, D. A., . . . Chaplin, W. (2011). Telephone-based mental health interventions for child disruptive behavior or anxiety disorders: Randomized trials and overall analysis. *Journal of the American Academy of Child & Adolescent Psychiatry, 50*, 1162–1172.
27. Cartwright-Hatton, S., McNally, D., Field, A. P., Rust, S., Laskey, B., Dixon, C., . . . Woodham, A. (2011). A new parenting-based group intervention for young anxious children: results of a randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 50*, 242–251.
28. Beidel, D. C., Turner, S. M., Sallee, F. R., Ammerman, R. T., Crosby, L. A., & Pathak, S. (2007). SET-C versus fluoxetine in the treatment of childhood social phobia. *Journal of the American Academy of Child & Adolescent Psychiatry, 46*, 1622–1632.
29. Birmaher, B., Axelson, D. A., Monk, K., Kalas, C., Clark, D. B., Ehmann, M., . . . Brent, D. A. (2003). Fluoxetine for the treatment of childhood anxiety disorders. *Journal of the American Academy of Child & Adolescent Psychiatry, 42*, 415–423.
30. Rynn, M. A., Siqueland, L., & Rickels, K. (2001). Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. *American Journal of Psychiatry, 158*, 2008–2014.
31. Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., . . . Kendall, P. C. (2008). Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. *New England Journal of Medicine, 359*, 2753–2766.
32. Jones, K., Daley, D., Hutchings, J., Bywater, T., & Eames, C. (2008). Efficacy of the Incredible Years Programme as an early intervention for children with conduct problems and ADHD: Long-term follow-up. *Child Care Health and Development, 34*, 380–390.

33. Scott, S., Sylva, K., Doolan, M., Price, J., Jacobs, B., Crook, C., & Landau, S. (2010). Randomised controlled trial of parent groups for child antisocial behaviour targeting multiple risk factors: The SPOKES project. *Journal of Child Psychology and Psychiatry*, *51*, 48–57.
34. Sylva, K., Scott, S., Totsika, V., Ereky-Stevens, K., & Crook, C. (2008). Training parents to help their children read: A randomized control trial. *British Journal of Educational Psychology*, *78*, 435–455.
35. Kaminski, J. W., Perou, R., Visser, S. N., Scott, K. G., Beckwith, L., Howard, J., . . . Danielson, M. L. (2013). Behavioral and socioemotional outcomes through age 5 years of the Legacy for Children public health approach to improving developmental outcomes among children born into poverty. *American Journal of Public Health*, *103*, 1058–1066.
36. Perou, R., Elliott, M. N., Visser, S. N., Claussen, A. H., Scott, K. G., Beckwith, L. H., . . . Smith, D. C. (2012). Legacy for Children™: A pair of randomized controlled trials of a public health model to improve developmental outcomes among children in poverty. *BMC Public Health*, *12*, 1–22.
37. Fowler, P. J., Henry, D. B., Schoeny, M., Gorman-Smith, D., & Tolan, P. H. (2014). Effects of the SAFE Children preventive intervention on developmental trajectories of attention-deficit/hyperactivity disorder symptoms. *Development and Psychopathology*, *26*, 1161–1179.
38. Tolan, P., Gorman-Smith, D., & Henry, D. (2004). Supporting families in a high-risk setting: Proximal effects of the SAFEChildren preventive intervention. *Journal of Consulting and Clinical Psychology*, *72*, 855–869.
39. The Incredible Years. (2013). *Incredible Years®: Parents, teachers, and children training series*. Retrieved August 2020, from <http://www.incredibleyears.com>
40. Lange, A. M., Daley, D., Frydenberg, M., Houmann, T., Kristensen, L. J., Rask, C., . . . Thomsen, P. H. (2018). Parent training for preschool ADHD in routine, specialist care: A randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *57*, 593–602.
41. Ferrin, M., Moreno-Granados, J. M., Salcedo-Marin, M. D., Ruiz-Veguilla, M., Perez-Ayala, V., & Taylor, E. (2014). Evaluation of a psychoeducation programme for parents of children and adolescents with ADHD: Immediate and long-term effects using a blind randomized controlled trial. *European Child & Adolescent Psychiatry*, *23*, 637–647.
42. Tutty, S., Gephart, H., & Wurzbacher, K. (2003). Enhancing behavioral and social skill functioning in children newly diagnosed with attention-deficit hyperactivity disorder in a pediatric setting. *Journal of Developmental and Behavioral Pediatrics*, *24*, 51–57.
43. Pfiffner, L. J., & McBurnett, K. (1997). Social skills training with parent generalization: Treatment effects for children with attention deficit disorder. *Journal of Consulting and Clinical Psychology*, *65*, 749–757.
44. King, S., Griffin, S., Hodges, Z., Weatherly, H., Asseburg, C., Richardson, G., . . . Riemsmma, R. (2006). A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. *Health Technology Assessment*, *10*, 1–146.
45. Van der Oord, S., Prins, P. J., Oosterlaan, J., & Emmelkamp, P. M. (2008). Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. *Clinical Psychology Review*, *28*, 783–800.
46. Heinrichs, N., Kliem, S., & Hahlweg, K. (2017). Addendum to "Four-year follow-up of a randomized controlled trial of Triple P Group for parent and child outcomes". *Prevention Science*, *18*, 491–503.
47. Hahlweg, K., Heinrichs, N., Kuschel, A., Bertram, H., & Naumann, S. (2010). Long-term outcome of a randomized controlled universal prevention trial through a positive parenting program: Is it worth the effort? *Child and Adolescent Psychiatry and Mental Health*, *4*, 1–14.
48. Averdijk, M., Zirk-Sadowski, J., Ribeaud, D., & Eisner, M. (2016). Long-term effects of two childhood psychosocial interventions on adolescent delinquency, substance use, and antisocial behavior: A cluster randomized controlled trial. *Journal of Experimental Criminology*, *12*, 21–47.

49. Malti, T., Ribeaud, D., & Eisner, M. P. (2011). The effectiveness of two universal preventive interventions in reducing children's externalizing behavior: A cluster randomized controlled trial. *Journal of Clinical Child and Adolescent Psychology, 40*, 677–692.
50. Breitenstein, S. M., Gross, D., Fogg, L., Ridge, A., Garvey, C., Julion, W., & Tucker, S. (2012). The Chicago Parent Program: Comparing 1-year outcomes for African American and Latino parents of young children. *Research in Nursing & Health, 35*, 475–489.
51. Hutchings, J., Bywater, T., Daley, D., Gardner, F., Whitaker, C., Jones, K., . . . Edwards, R. T. (2007). Parenting intervention in Sure Start services for children at risk of developing conduct disorder: Pragmatic randomised controlled trial. *British Medical Journal, 334*, 1–7.
52. Brotman, L. M., Gouley, K. K., Huang, K. Y., Rosenfelt, A., O'Neal, C., Klein, R. G., & Shrout, P. (2008). Preventive intervention for preschoolers at high risk for antisocial behavior: Long-term effects on child physical aggression and parenting practices. *Journal of Clinical Child and Adolescent Psychology, 37*, 386–396.
53. Olds, D., Henderson, C. R., Cole, R., Eckenrode, J., Kitzman, H., Luckey, D., . . . Powers, J. (1998). Long-term effects of nurse home visitation on children's criminal and antisocial behavior: 15-year follow-up of a randomized controlled trial. *Journal of the American Medical Association, 280*, 1238–1244.
54. Forgatch, M. S., Patterson, G. R., Degarmo, D. S., & Beldavs, Z. G. (2009). Testing the Oregon delinquency model with 9-year follow-up of the Oregon Divorce Study. *Development and Psychopathology, 21*, 637–660.
55. Sourander, A., McGrath, P. J., Ristkari, T., Cunningham, C., Huttunen, J., Lingley-Pottie, P., . . . Unruh, A. (2016). Internet-assisted parent training intervention for disruptive behavior in 4-year-old children: A randomized clinical trial. *JAMA Psychiatry, 73*, 378–387.
56. Sourander, A., McGrath, P. J., Ristkari, T., Cunningham, C., Huttunen, J., Hinkka-Yli-Salomaki, S., . . . Lingley-Pottie, P. (2018). Two-year follow-up of internet and telephone assisted parent training for disruptive behavior at age 4. *Journal of the American Academy of Child & Adolescent Psychiatry, 57*, 658–668.
57. Day, J. J., & Sanders, M. R. (2018). Do parents benefit from help when completing a self-guided parenting program online? A randomized controlled trial comparing Triple P Online with and without telephone support. *Behavior Therapy, 49*, 1020–1038.
58. Baker, S., Sanders, M. R., Turner, K. M. T., & Morawska, A. (2017). A randomized controlled trial evaluating a low-intensity interactive online parenting intervention, Triple P Online Brief, with parents of children with early onset conduct problems. *Behaviour Research and Therapy, 91*, 78–90.
59. Schwartz, C., Waddell, C., Barican, J., Andres, C., & Gray-Grant, D. (2015). Promoting positive behaviour in children. *Children's Mental Health Research Quarterly, 9*, 1–20. Vancouver, BC: Children's Health Policy Centre, Faculty of Health Sciences, Simon Fraser University.
60. Kellam, S. G., Brown, C. H., Poduska, J. M., Ialongo, N. S., Wang, W., Toyinbo, P., . . . Wilcox, H. C. (2008). Effects of a universal classroom behavior management program in first and second grades on young adult behavioral, psychiatric, and social outcomes. *Drug and Alcohol Dependence, 95*, S5–S28.
61. Musci, R. J., Bradshaw, C. P., Maher, B., Uhl, G. R., Kellam, S. G., & Ialongo, N. S. (2014). Reducing aggression and impulsivity through school-based prevention programs: A gene by intervention interaction. *Prevention Science, 15*, 831–840.
62. Ialongo, N., Poduska, J., Werthamer, L., & Kellam, S. (2001). The distal impact of two first-grade preventive interventions on conduct problems and disorder in early adolescence. *Journal of Emotional and Behavioral Disorders, 9*, 146–160.
63. Dodge, K. A., Bierman, K. L., Cole, J. D., Greenberg, M. T., Lochman, J. E., McMahon, R. J., . . . Conduct Problems Prevention Research Group. (2015). Impact of early intervention on psychopathology, crime, and well-being at age 25. *American Journal of Psychiatry, 172*, 59–70.

64. Bierman, K. L., Coie, J. D., Dodge, K. A., Greenberg, M. T., Lochman, J. E., McMahon, R. J., . . . Conduct Problems Prevention Research Group. (2011). The effects of the Fast Track preventive intervention on the development of conduct disorder across childhood. *Child Development, 82*, 331–345.
65. Schweinhart, L. J. (2013). Long-term follow-up of a preschool experiment. *Journal of Experimental Criminology, 9*, 389–409.
66. Scott, S., Briskman, J., & O'Connor, T. G. (2014). Early prevention of antisocial personality: Long-term follow-up of two randomized controlled trials comparing indicated and selective approaches. *American Journal of Psychiatry, 171*, 649–657.
67. Scott, S., Spender, Q., Doolan, M., Jacobs, B., & Aspland, H. (2001). Multicentre controlled trial of parenting groups for childhood antisocial behaviour in clinical practice. *British Medical Journal, 323*, 194–197.
68. Bjørseth, A., & Wichstrom, L. (2016). Effectiveness of parent-child interaction therapy (PCIT) in the treatment of young children's behavior problems: A randomized controlled study. *PloS One, 11*, e0159845.
69. Dembo, R., Schmeidler, J., Wareham, J., Briones-Robinson, R., Winters, K. C., & Ungaro, R. (2016). Impact of brief intervention services on drug-using truant youths' self-reported delinquency and arrest charges: A longitudinal study. *Journal of Child & Adolescent Substance Abuse, 25*, 458–479.
70. Eddy, J. M., Whaley, R. B., & Chamberlain, P. (2004). The prevention of violent behavior by chronic and serious male juvenile offenders: A 2-year follow-up of a randomized clinical trial. *Journal of Emotional and Behavioral Disorders, 12*, 2–8.
71. Chamberlain, P., & Reid, J. B. (1998). Comparison of two community alternatives to incarceration for chronic juvenile offenders. *Journal of Consulting and Clinical Psychology, 66*, 624–633.
72. Chamberlain, P., Leve, L. D., & DeGarmo, D. S. (2007). Multidimensional treatment foster care for girls in the juvenile justice system: 2-year follow-up of a randomized clinical trial. *Journal of Consulting and Clinical Psychology, 75*, 187–193.
73. Letourneau, E. J., Henggeler, S. W., McCart, M. R., Borduin, C. M., Schewe, P. A., & Armstrong, K. S. (2013). Two-year follow-up of a randomized effectiveness trial evaluating MST for juveniles who sexually offend. *Journal of Family Psychology, 27*, 978–985.
74. Buitelaar, J. K., van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. M. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. *Journal of Clinical Psychiatry, 62*, 239–248.
75. Findling, R. L., McNamara, N. K., Branicky, L. A., Schluchter, M. D., Lemon, E., & Blumer, J. L. (2000). A double-blind pilot study of risperidone in the treatment of conduct disorder. *Journal of the American Academy of Child and Adolescent Psychiatry, 39*, 509–516.
76. Aman, M. G., De Smedt, G., Derivan, A., Lyons, B., Findling, R. L., & Risperidone Disruptive Behavior Study Group. (2002). Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. *American Journal of Psychiatry, 159*, 1337–1346.
77. Spoth, R., Trudeau, L., Guyll, M., Shin, C., & Redmond, C. (2009). Universal intervention effects on substance use among young adults mediated by delayed adolescent substance initiation. *Journal of Consulting and Clinical Psychology, 77*, 620–632.
78. Spoth, R. L., Randall, G. K., Trudeau, L., Shin, C., & Redmond, C. (2008). Substance use outcomes 5½ years past baseline for partnership-based, family-school preventive interventions. *Drug and Alcohol Dependence, 96*, 57–68.
79. Spoth, R., Randall, G. K., Shin, C., & Redmond, C. (2005). Randomized study of combined universal family and school preventive interventions: Patterns of long-term effects on initiation, regular use, and weekly drunkenness. *Psychology of Addictive Behaviors, 19*, 372–381.

80. Mason, W. A., Kosterman, R., Haggerty, K. P., Hawkins, J. D., Redmond, C., Spoth, R. L., & Shin, C. (2009). Gender moderation and social developmental mediation of the effect of a family-focused substance use preventive intervention on young adult alcohol abuse. *Addict Behav*, *34*(6-7), 599-605.
81. Shek, D. T. L., & Lee, T. Y. (2012). Helping adolescents with greater psychosocial needs: Subjective outcome evaluation based on different cohorts. *Scientific World Journal*, 1-10.
82. Shek, D. T. L., & Sun, R. C. F. (2013). The Project PATHS in Hong Kong: Development, training, implementation, and evaluation. *Journal of Pediatric and Adolescent Gynecology*, *26*, S2-S9.
83. Shek, D. T. L., & Yu, L. (2012). Longitudinal impact of the Project PATHS on adolescent risk behavior: What happened after five years? *Scientific World Journal*, *2012*, 1-13.
84. Schinke, S. P., Fang, L., & Cole, K. C. (2009). Preventing substance use among adolescent girls: 1-year outcomes of a computerized, mother-daughter program. *Addictive Behaviors*, *34*, 1060-1064.
85. Faggiano, F., Vigna-Taglianti, F., Burkhardt, G., Bohrn, K., Cuomo, L., Gregori, D., . . . Grp, E.-D. S. (2010). The effectiveness of a school-based substance abuse prevention program: 18-month follow-up of the EU-DAP cluster randomized controlled trial. *Drug and Alcohol Dependence*, *108*, 56-64.
86. Gabrhelik, R., Duncan, A., Miovisky, M., Furr-Holden, C. D. M., Stastna, L., & Jurystova, L. (2012). "Unplugged": A school-based randomized control trial to prevent and reduce adolescent substance use in the Czech Republic. *Drug and Alcohol Dependence*, *124*, 79-87.
87. Spoth, R., Redmond, C., & Shin, C. (1998). Direct and indirect latent-variable parenting outcomes of two universal family-focused preventive interventions: Extending a public health-oriented research base. *Journal of Consulting and Clinical Psychology*, *66*, 385-399.
88. Kim, H. K., & Leve, L. D. (2011). Substance use and delinquency among middle school girls in foster care: A three-year follow-up of a randomized controlled trial. *Journal of Consulting and Clinical Psychology*, *79*, 740-750.
89. Shek, D. T. L., Lee, T. Y., & Sun, R. C. F. (2008). Process evaluation of the implementation of the Secondary 2 program of Project PATHS in the experimental implementation phase. *Scientific World Journal*, *8*, 83-94.
90. D'Amico, E. J., Parast, L., Shadel, W. G., Meredith, L. S., Seelam, R., & Stein, B. D. (2018). Brief motivational interviewing intervention to reduce alcohol and marijuana use for at-risk adolescents in primary care. *Journal of Consulting and Clinical Psychology*, *86*, 775-786.
91. Conrod, P. J., Castellanos-Ryan, N., & Strang, J. (2010). Brief, personality-targeted coping skills interventions and survival as a non-drug user over a 2-year period during adolescence. *Archives of General Psychiatry*, *67*, 85-93.
92. Conrod, P. J., Castellanos-Ryan, N., & Mackie, C. (2011). Long-term effects of a personality-targeted intervention to reduce alcohol use in adolescents. *Journal of Consulting and Clinical Psychology*, *79*, 296-306.
93. Conrod, P. J., O'Leary-Barrett, M., Newton, N., Topper, L., Castellanos-Ryan, N., Mackie, C., & Girard, A. (2013). Effectiveness of a selective, personality-targeted prevention program for adolescent alcohol use and misuse: A cluster randomized controlled trial. *JAMA Psychiatry*, *70*, 334-342.
94. Mahu, I. T., Doucet, C., O'Leary-Barrett, M., & Conrod, P. J. (2015). Can cannabis use be prevented by targeting personality risk in schools? Twenty-four-month outcome of the adventure trial on cannabis use: A cluster-randomized controlled trial. *Addiction*, *110*, 1625-1633.
95. Stern, S. A., Meredith, L. S., Gholson, J., Gore, P., & D'Amico, E. J. (2007). Project CHAT: A brief motivational substance abuse intervention for teens in primary care. *Journal of Substance Abuse Treatment*, *32*, 153-165.
96. Martin, G., & Copeland, J. (2008). The adolescent cannabis check-up: Randomized trial of a brief intervention for young cannabis users. *Journal of Substance Abuse Treatment*, *34*, 407-414.
97. Winters, K. C., & Leitten, W. (2007). Brief intervention for drug-abusing adolescents in a school setting. *Psychology of Addictive Behaviors*, *21*, 249-254.

98. Latimer, W. W., Winters, K. C., D'Zurilla, T., & Nichols, M. (2003). Integrated family and cognitive-behavioral therapy for adolescent substance abusers: A stage I efficacy study. *Drug and Alcohol Dependence*, *71*, 303–317.
99. Rigter, H., Henderson, C. E., Pelc, I., Tossmann, P., Phan, O., Hendriks, V., . . . Rowe, C. L. (2013). Multidimensional family therapy lowers the rate of cannabis dependence in adolescents: A randomised controlled trial in Western European outpatient settings. *Drug and Alcohol Dependence*, *130*, 85–93.
100. Liddle, H. A., Dakof, G. A., Turner, R. M., Henderson, C. E., & Greenbaum, P. E. (2008). Treating adolescent drug abuse: A randomized trial comparing multidimensional family therapy and cognitive behavior therapy. *Addiction*, *103*, 1660–1670.
101. Liddle, H. A., Rowe, C. L., Dakof, G. A., Henderson, C. E., & Greenbaum, P. E. (2009). Multidimensional family therapy for young adolescent substance abuse: Twelve-month outcomes of a randomized controlled trial. *Journal of Consulting and Clinical Psychology*, *77*, 12–25.
102. Clarke, G. N., Hawkins, W., Murphy, M., Sheeber, L. B., Lewinsohn, P. M., & Seeley, J. R. (1995). Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: A randomized trial of a group cognitive intervention. *Journal of the American Academy of Child & Adolescent Psychiatry*, *34*, 312–321.
103. Clarke, G. N., Hornbrook, M., Lynch, F., Polen, M., Gale, J., Beardslee, W., . . . Seeley, J. (2001). A randomized trial of a group cognitive intervention for preventing depression in adolescent offspring of depressed parents. *Archives of General Psychiatry*, *58*, 1127–1134.
104. Stice, E., Rohde, P., Seeley, J. R., & Gau, J. M. (2008). Brief cognitive-behavioral depression prevention program for high-risk adolescents outperforms two alternative interventions: A randomized efficacy trial. *Journal of Consulting and Clinical Psychology*, *76*, 595–606.
105. Rohde, P., Stice, E., Shaw, H., & Briere, F. N. (2014). Indicated cognitive behavioral group depression prevention compared to bibliotherapy and brochure control: Acute effects of an effectiveness trial with adolescents. *Journal of Consulting and Clinical Psychology*, *82*, 65–74.
106. Rohde, P., Stice, E., Shaw, H., & Gau, J. M. (2015). Effectiveness trial of an indicated cognitive-behavioral group adolescent depression prevention program versus bibliotherapy and brochure control at 1-and 2-year follow-up. *Journal of Consulting and Clinical Psychology*, *83*, 736–747.
107. Compas, B. E., Forehand, R., Thigpen, J. C., Keller, G., Hardcastle, E. J., Cole, D. A., . . . Roberts, L. (2011). Family group cognitive-behavioral preventive intervention for families of depressed parents: 18- and 24-month outcomes. *Journal of Consulting and Clinical Psychology*, *79*, 488–499.
108. Arnarson, E. O., & Craighead, W. E. (2011). Prevention of depression among Icelandic adolescents: A 12-month follow-up. *Behaviour Research and Therapy*, *49*, 170–174.
109. Burns, D. D. (1980). *Feeling Good: The new mood therapy*. William Morrow and Company.
110. Zhou, X., Hetrick, S. E., Cuijpers, P., Qin, B., Barth, J., Whittington, C. J., . . . Xie, P. (2015). Comparative efficacy and acceptability of psychotherapies for depression in children and adolescents: A systematic review and network meta-analysis. *World Psychiatry*, *14*, 207–222.
111. Mufson, L., Dorta, K. P., Wickramaratne, P., Nomura, Y., Olfson, M., & Weissman, M. M. (2004). A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. *Archives of General Psychiatry*, *61*, 577–584.
112. March, J., Silva, S., & Vitiello, B. (2006). The Treatment for Adolescents with Depression Study (TADS): Methods and message at 12 weeks. *Journal of the American Academy of Child & Adolescent Psychiatry*, *45*, 1393–1403.
113. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., & Rintelmann, J. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. *Archives of General Psychiatry*, *54*, 1031–1037.

114. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., . . . Jacobson, J. G. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *41*, 1205–1215.
115. Riggs, P. D., Mikulich-Gilbertson, S. K., Davies, R. D., Lohman, M., Klein, C., & Stover, S. K. (2007). A randomized controlled trial of fluoxetine and cognitive behavioral therapy in adolescents with major depression, behavior problems, and substance use disorders. *Archives of Pediatric and Adolescent Medicine*, *161*, 1026–1034.
116. Emslie, G., Kratochvil, C., Vitiello, B., Silva, S., Mayes, T., McNulty, S., . . . March, J. (2006). Treatment for Adolescents with Depression Study (TADS): Safety results. *Journal of the American Academy of Child & Adolescent Psychiatry*, *45*, 1440–1455.
117. Ameis, S. H., Kasse, C., Corbett-Dick, P., Cole, L., Dadhwal, S., Lai, M. C., . . . Correll, C. U. (2018). Systematic review and guide to management of core and psychiatric symptoms in youth with autism. *Acta Psychiatrica Scandinavica*, *138*, 379–400.
118. Kasari, C., Gulsrud, A., Paparella, T., Helleman, G., & Berry, K. (2015). Randomized comparative efficacy study of parent-mediated interventions for toddlers with autism. *Journal of Consulting and Clinical Psychology*, *83*, 554–563.
119. Kasari, C., Kaiser, A., Goods, K., Nietfeld, J., Mathy, P., Landa, R., . . . Almirall, D. (2014). Communication interventions for minimally verbal children with autism: A sequential multiple assignment randomized trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *53*, 635–646.
120. Solomon, R., Van Egeren, L. A., Mohoney, G., Huber, M. S. Q., & Zimmerman, P. (2014). PLAY Project home consultation intervention program for young children with autism spectrum disorders: A randomized controlled trial. *Journal of Developmental and Behavioral Pediatrics*, *35*, 475–485.
121. Hardan, A. Y., Gengoux, G. W., Berquist, K. L., Libove, R. A., Ardel, C. M., Phillips, J., . . . Minjarez, M. B. (2015). A randomized controlled trial of Pivotal Response Treatment Group for parents of children with autism. *Journal of Child Psychology and Psychiatry*, *56*, 884–892.
122. Kasari, C., Lawton, K., Shih, W., Barker, T. V., Landa, R., Lord, C., . . . Senturk, D. (2014). Caregiver-mediated intervention for low-resourced preschoolers with autism: An RCT. *Pediatrics*, *134*, e72–e79.
123. Rice, L. M., Wall, C. A., Fogel, A., & Shic, F. (2015). Computer-assisted face processing instruction improves emotion recognition, mentalizing, and social skills in students with ASD. *Journal of Autism Development Disorders*, *45*, 2176–2186.
124. Begeer, S., Howlin, P., Hoddenbach, E., Clauser, C., Lindauer, R., Clifford, P., . . . Koot, H. M. (2015). Effects and moderators of a short theory of mind intervention for children with autism spectrum disorder: A randomized controlled trial. *Autism Research*, *8*, 738–748.
125. Soorya, L. V., Siper, P. M., Beck, T., Soffes, S., Halpern, D., Gorenstein, M., . . . Wang, A. T. (2015). Randomized comparative trial of a social cognitive skills group for children with autism spectrum disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, *54*, 208–216.
126. Williams, T. I., Salkovskis, P. M., Forrester, L., Turner, S., White, H., & Allsopp, M. A. (2010). A randomised controlled trial of cognitive behavioural treatment for obsessive compulsive disorder in children and adolescents. *European Child and Adolescent Psychiatry*, *19*, 449–456.
127. Bolton, D., Williams, T., Perrin, S., Atkinson, L., Gallop, C., Waite, P., & Salkovskis, P. (2011). Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. *Journal of Child Psychology and Psychiatry*, *52*, 1269–1278.
128. Turner, C. M., Mataix-Cols, D., Lovell, K., Krebs, G., Lang, K., Byford, S., & Heyman, I. (2014). Telephone cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: A randomized controlled non-inferiority trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *53*, 1298–1307.

129. Lewin, A. B., Park, J. M., Jones, A. M., Crawford, E. A., De Nadai, A. S., Menzel, J., . . . Storch, E. A. (2014). Family-based exposure and response prevention therapy for preschool-aged children with obsessive-compulsive disorder: A pilot randomized controlled trial. *Behaviour Research and Therapy*, *56*, 30–38.
130. Freeman, J., Sapyta, J., Garcia, A., Compton, S., Khanna, M., Flessner, C., . . . Franklin, M. (2014). Family-based treatment of early childhood obsessive-compulsive disorder: The Pediatric Obsessive-Compulsive Disorder Treatment Study for Young Children (POTS Jr): A randomized clinical trial. *JAMA Psychiatry*, *71*, 689–698.
131. Storch, E. A., Caporino, N. E., Morgan, J. R., Lewin, A. B., Rojas, A., Brauer, L., . . . Murphy, T. K. (2011). Preliminary investigation of web-camera delivered cognitive-behavioral therapy for youth with obsessive-compulsive disorder. *Psychiatry Research*, *189*, 407–412.
132. Piacentini, J., Bergman, R. L., Chang, S., Langley, A., Peris, T., Wood, J. J., & McCracken, J. (2011). Controlled comparison of family cognitive behavioral therapy and psychoeducation/relaxation training for child obsessive-compulsive disorder. *Journal of the American Academy of Child & Adolescent Psychiatry*, *50*, 1149–1161.
133. Lenhard, F., Andersson, E., Mataix-Cols, D., Ruck, C., Vigerland, S., Hogstrom, J., . . . Serlachius, E. (2017). Therapist-guided, internet-delivered cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: A randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *56*, 10–19.
134. Peris, T. S., Rozenman, M. S., Sugar, C. A., McCracken, J. T., & Piacentini, J. (2017). Targeted family intervention for complex cases of pediatric obsessive-compulsive disorder: A randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *56*, 1034–1042.
135. Schwartz, C., Waddell, C., Barican, J., Gray-Grant, D., Mughal, S., & Nightingale, L. (2014). Treating childhood obsessive-compulsive disorder. *Children's Mental Health Research Quarterly*, *8*, 1–16. Vancouver, BC: Children's Health Policy Centre, Faculty of Health Sciences, Simon Fraser University.
136. Watson, H. J., & Rees, C. S. (2008). Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder. *Journal of Child Psychology and Psychiatry*, *49*, 489–498.
137. Canadian Pharmacists' Association. (2020). *Compendium of Pharmaceuticals and Specialities*. Ottawa, ON: Canadian Pharmacists' Association.
138. Fristad, M. A., Verducci, J. S., Walters, K., & Young, M. E. (2009). Impact of multifamily psychoeducational psychotherapy in treating children aged 8 to 12 years with mood disorders. *Archives of General Psychiatry*, *66*, 1013–1021.
139. West, A. E., Weinstein, S. M., Peters, A. T., Katz, A. C., Henry, D. B., Cruz, R. A., & Pavuluri, M. N. (2014). Child- and family-focused cognitive-behavioral therapy for pediatric bipolar disorder: a randomized clinical trial. *Journal of the American Academy of Child & Adolescent Psychiatry*, *53*, 1168–1178.
140. Miklowitz, D. J., Axelson, D. A., Birmaher, B., George, E. L., Taylor, D. O., Schneck, C. D., . . . Brent, D. A. (2008). Family-focused treatment for adolescents with bipolar disorder: Results of a 2-year randomized trial. *Archives of General Psychiatry*, *65*, 1053–1061.
141. Miklowitz, D. J., Schneck, C. D., Singh, M. K., Taylor, D. O., George, E. L., Cosgrove, V. E., . . . Chang, K. D. (2013). Early intervention for symptomatic youth at risk for bipolar disorder: A randomized trial of family-focused therapy. *Journal of the American Academy of Child & Adolescent Psychiatry*, *52*, 121–131.
142. Geller, B., Cooper, T. B., Sun, K., Zimmerman, B., Frazier, J., Williams, M., & Heath, J. (1998). Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency. *Journal of the American Academy of Child & Adolescent Psychiatry*, *37*, 171–178.
143. Findling, R. L., Robb, A., McNamara, N. K., Pavuluri, M. N., Kafantaris, V., Scheffer, R., . . . Taylor-Zapata, P. (2015). Lithium in the acute treatment of bipolar I disorder: A double-blind, placebo-controlled study. *Pediatrics*, *136*, 885–894.

144. Favaro, A., Zanetti, T., Huon, G., & Santonastaso, P. (2005). Engaging teachers in an eating disorder preventive intervention. *International Journal of Eating Disorders*, *38*, 73–77.
145. Stice, E., Shaw, H., Burton, E., & Wade, E. (2006). Dissonance and healthy weight eating disorder prevention programs: a randomized efficacy trial. *Journal of Consulting and Clinical Psychology*, *74*, 263–275.
146. Stice, E., Marti, C. N., Spoor, S., Presnell, K., & Shaw, H. (2008). Dissonance and healthy weight eating disorder prevention programs: Long-term effects from a randomized efficacy trial. *Journal of Consulting and Clinical Psychology*, *76*, 329–340.
147. Stice, E., Rohde, P., Gau, J., & Shaw, H. (2009). An effectiveness trial of a dissonance-based eating disorder prevention program for high-risk adolescent girls. *Journal of Consulting and Clinical Psychology*, *77*, 825–834.
148. Stice, E., Rohde, P., Shaw, H., & Gau, J. (2011). An effectiveness trial of a selected dissonance-based eating disorder prevention program for female high school students: Long-term effects. *Journal of Consulting and Clinical Psychology*, *79*, 500–508.
149. Stice, E., Presnell, K., Groesz, L., & Shaw, H. (2005). Effects of a weight maintenance diet on bulimic symptoms in adolescent girls: An experimental test of the dietary restraint theory. *Health Psychology*, *24*, 402–412.
150. Jones, M., Luce, K. H., Osborne, M. I., Taylor, K., Cunning, D., Doyle, A. C., . . . Taylor, C. B. (2008). Randomized, controlled trial of an internet-facilitated intervention for reducing binge eating and overweight in adolescents. *Pediatrics*, *121*, 453–462.
151. Couturier, J., Kimber, M., & Szatmari, P. (2013). Efficacy of family-based treatment for adolescents with eating disorders: a systematic review and meta-analysis. *International Journal of Eating Disorders*, *46*, 3–11.
152. Lock, J., & Le Grange, D. (2001). Can family-based treatment of anorexia nervosa be manualized? *Journal of Psychotherapy Practice and Research*, *10*, 253–261.
153. Lock, J., Le Grange, D., Agras, W. S., Moye, A., Bryson, S. W., & Jo, B. (2010). Randomized clinical trial comparing family-based treatment with adolescent-focused individual therapy for adolescents with anorexia nervosa. *Archives of General Psychiatry*, *67*, 1025–1032.
154. Le Grange, D., Lock, J., Agras, W. S., Bryson, S. W., & Jo, B. (2015). Randomized clinical trial of family-based treatment and cognitive-behavioral therapy for adolescent bulimia nervosa. *Journal of the American Academy of Child & Adolescent Psychiatry*, *54*, 886–894.
155. Taussig, H. N., & Culhane, S. E. (2010). Impact of a mentoring and skills group program on mental health outcomes for maltreated children in foster care. *Archives of Pediatric and Adolescent Medicine*, *164*, 739–746.
156. Taussig, H. N., Culhane, S. E., Garrido, E., Knudtson, M. D., & Petrenko, C. L. (2013). Does severity of physical neglect moderate the impact of an efficacious preventive intervention for maltreated children in foster care? *Child Maltreatment*, *18*, 56–64.
157. Taussig, H. N., Weiler, L. M., Garrido, E. F., Rhodes, T., Boat, A., & Fadell, M. (2019). A positive youth development approach to improving mental health outcomes for maltreated children in foster care: Replication and extension of an RCT of the Fostering Healthy Futures program. *American Journal of Community Psychology*, *64*, 405–417.
158. Overbeek, M. M., de Schipper, J. C., Lamers-Winkelmann, F., & Schuengel, C. (2013). Effectiveness of specific factors in community-based intervention for child-witnesses of interparental violence: A randomized trial. *Child Abuse & Neglect*, *37*, 1202–1214.
159. Swenson, C. C., Schaeffer, C. M., Henggeler, S. W., Faldowski, R., & Mayhew, A. M. (2010). Multisystemic therapy for child abuse and neglect: A randomized effectiveness trial. *Journal of Family Psychology*, *24*, 497–507.

160. Danielson, C. K., McCart, M. R., Walsh, K., de Arellano, M. A., White, D., & Resnick, H. S. (2012). Reducing substance use risk and mental health problems among sexually assaulted adolescents: A pilot randomized controlled trial. *Journal of Family Psychology, 26*, 628–635.
161. Gilboa-Schechtman, E., Foa, E. B., Shafran, N., Aderka, I. M., Powers, M. B., Rachamim, L., . . . Apter, A. (2010). Prolonged exposure versus dynamic therapy for adolescent PTSD: A pilot randomized controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 49*, 1034–1042.
162. Foa, E. B., McLean, C. P., Capaldi, S., & Rosenfield, D. (2013). Prolonged exposure vs supportive counseling for sexual abuse-related PTSD in adolescent girls: A randomized clinical trial. *Journal of the American Medical Association, 310*, 2650–2657.
163. Ruf, M., Schauer, M., Neuner, F., Catani, C., Schauer, E., & Elbert, T. (2010). Narrative exposure therapy for 7- to 16-year-olds: A randomized controlled trial with traumatized refugee children. *Journal of Traumatic Stress, 23*, 437–445.
164. Findling, R. L., Robb, A., Nyilas, M., Forbes, R. A., Jin, N., Ivanova, S., . . . Carson, W. H. (2008). A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. *American Journal of Psychiatry, 165*, 1432–1441.
165. Pagsberg, A. K., Jeppesen, P., Klauber, D. G., Jensen, K. G., Ruda, D., Stentebjerg-Olesen, M., . . . Fink-Jensen, A. (2017). Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: The multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. *Lancet Psychiatry, 4*, 605–618.
166. Kryzhanovskaya, L., Schulz, S. C., McDougle, C., Frazier, J., Dittmann, R., Robertson-Plouch, C., . . . Tohen, M. (2009). Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 48*, 60–70.
167. Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., . . . Rapoport, J. L. (2006). Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. *Archives of General Psychiatry, 63*, 721–730.
168. Canadian Institute for Health Information. (2019). *National health expenditure trends, 1975 to 2019*. Ottawa, ON: Canadian Institute for Health Information.
169. Government of British Columbia. (n.d.) *Ministry of Children and Family Development*. Retrieved September 2020, from <https://www2.gov.bc.ca/gov/content/governments/organizational-structure/ministries-organizations/ministries/children-and-family-development>
170. Catherine, N. L. A., Gonzales, A., Boyle, M., Sheehan, D., Jack, S. M., Hougham, K. A., . . . Waddell, C. (2016). Improving children’s health and development in British Columbia through nurse home visiting: A randomized controlled trial protocol. *BMC Health Services, 16*, 1–13.
171. Catherine, N. L. A., Lever, R., Sheehan, D., Zheng, Y., Boyle, M. H., McCandless, L., . . . Waddell, C. (2019). The British Columbia Healthy Connections Project: Findings on socioeconomic disadvantage in early pregnancy. *BMC Public Health, 19*, 1–11.
172. Children’s Health Policy Centre. (2020). *BC Healthy Connections Project*. Retrieved September 2020, from <https://childhealthpolicy.ca/bc-healthy-connections-project/>
173. McDaid, D., Park, A., & Wahlbeck, K. (2019). The economic case for the prevention of mental illness. *Annual Review of Public Health, 40*, 373–389.
174. Washington State Institute for Public Policy. (2019). *Benefit-cost technical documentation*. Olympia, WA: Washington State Institute for Public Policy.
175. Cohen, M. A., & Piquero, A. R. (2009). New evidence on the monetary value of saving a high risk youth. *Journal of Quantitative Criminology, 25*, 25–49.
176. Washington State Institute for Public Policy. (2019). *Benefit-cost results*. Retrieved September 2020, from <https://www.wsipp.wa.gov/BenefitCost>

177. Nores, M., Belfield, C. R., Barnett, W. S., & Schweinhart, L. (2005). Updating the economic impacts of the High/Scope Perry Preschool program. *Educational Evaluation and Policy Analysis*, 27, 245–261.
178. Therapeutics Initiative. (2018). Stimulants for ADHD in children: Revisited. *Therapeutics Letter*, 110. Vancouver, BC: Therapeutics Initiative, Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia.
179. Rosen, M. S. (2017). Lithium in child and adolescent bipolar disorder. *American Journal of Psychiatry Residents' Journal*, 12, 3–5.
180. Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotic Medications in Children (CAMESA). (2020). *CAMESA guidelines*. Retrieved September 2020, from <http://comesaguideline.org/information-for-doctors>
181. British Columbia Centre on Substance Use, BC Ministry of Health, & BC Ministry of Mental Health and Addictions. (2018). A Guideline for the clinical management of opioid use disorder: Youth supplement. Retrieved September 2020, from <http://www.bccsu.ca/care-guidance-publications>
182. Waddell, C., Schwartz, C., & Andres, C. (2018). Making children's mental health a public policy priority: For the one and the many. *Public Health Ethics*, 11, 191–200.
183. Kim-Cohen, J., Caspi, A., Moffitt, T. E., Harrington, H., Milne, B. J., & Poulton, R. (2003). Prior juvenile diagnoses in adults with mental disorder: Developmental follow-back of a prospective-longitudinal cohort. *Archives of General Psychiatry*, 60, 709–717.
184. Kessler, R. C., Angermeyer, M., Anthony, J. C., de Graaf, R., Demyttenaere, K., Gasquet, I., . . . Üstün, T.B. (2007). Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organization's World Mental Health Survey Initiative. *World Psychiatry*, 6, 168–176.
185. Matthijssen, A. M., Dietrich, A., Bierens, M., Kleine Deters, R., van de Loo-Neus, G. H. H., van den Hoofdakker, B. J., . . . Hoekstra, P. J. (2019). Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: A randomized placebo-controlled discontinuation study. *American Journal of Psychiatry*, 176, 754–762.
186. Pliszka, S. R., Wilens, T. E., Bostrom, S., Arnold, V. K., Marraffino, A., Cutler, A. J., . . . Newcorn, J. H. (2017). Efficacy and safety of HLD200, delayed-release and extended-release methylphenidate, in children with attention-deficit/hyperactivity disorder. *Journal of Child & Adolescent Psychopharmacology*, 27, 474–482.

Appendix: Study and Intervention Details

Anxiety Disorder Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age/Grade	Duration	Follow-up	Anxiety outcomes (Effect sizes)
Prevention – Universal					
MoodGYM ⁸	Self-directed child cognitive-behavioural therapy (CBT)	12–17 years	1¼ months	6 months	↓ 1 of 1 symptom (d=0.25)
Prevention – Targeted					
Cool Little Kids G ⁹	Parent CBT training	4 years	3 months	9 months	× Any diagnoses ↓ 1 of 1 symptom
Coping and Promoting Strength ¹⁰	Family CBT	7–12 years	5 months	9 months	↓ Any diagnoses ↓ 2 of 3 symptoms (d=0.82–1.99)
Coping and Promoting Strength ^{11–12}	Family CBT	6–13 years	5 months	9 months	↓ Any diagnoses (OR=8.54) ↓ 3 of 4 symptoms (d=0.54–0.74)
Friends G ¹³	Child CBT + parent education	Grade 7	5½ months	3¾ years	× Any diagnoses ↓ 1 of 2 symptoms
Psychosocial Treatment					
Cool Kids G ¹⁵	Child CBT + parent CBT training	7–16 years	2½ months	3 months	↓ Primary diagnoses ↓ Any diagnoses ↓ 3 of 6 symptoms
Cool Little Kids plus Social Skills G ¹⁶	Parent CBT training + child social skills training	2–5 years	2½ months	3 months	↓ Any diagnoses ↓ # of diagnoses (d=1.76) ↓ 3 of 5 symptoms (d=0.89–2.11)
Coping Cat ¹⁷	Child CBT	7–14 years	4 months	1 year	× Primary diagnoses ↓ 1 of 8 symptoms
Coping Cat ¹⁸	Child CBT	9–14 years	Not reported	1 year	↓ Any diagnoses (OR=3.29) ↓ 1 of 3 symptoms (OR=2.56)
Coping Koala G ¹⁹	Child CBT + parent CBT training	Grades 3–7	2½ months	2 years	↓ Any diagnoses ↓ 2 of 6 symptoms
Friends G ^{20–21}	Child CBT	Grades 2–5	5 months	3 months	× Primary diagnoses × New diagnoses
				2¾ years	↓ 1 of 5 symptoms
One-Session Treatment ²²	Child CBT	7–16 years	3 hours	6 months	↓ Primary diagnoses ↓ 1 of 6 symptoms
Parent Education Program G ²³	Parent CBT training	3–4 years	2½ months	3 years	↓ Any diagnoses ↓ 2 of 3 symptoms
Skills for Academic and Social Success G ²⁴	Child CBT + parent + teacher education	Grades 9–11	5 months	4 months	↓ Primary diagnoses ↓ 2 of 5 symptoms
Skills for Academic and Social Success G ²⁵	Child CBT + parent + teacher education	Grades 9–11	5 months	3 months	↓ Primary diagnoses (OR=4.89) ↓ 3 of 5 symptoms (OR=16.21; d=0.38–0.93)
Strongest Families – Chase Worries Away ²⁶	Self-directed family CBT with coaching	6–12 years	6½ months	5½ months	↓ Any diagnoses (OR=2.51)
Timid to Tiger G ²⁷	Parent CBT training	2–9 years	2½ months	1 year	↓ Primary diagnoses (OR=3.68) ↓ Any diagnoses (OR=8.50) × 3 of 3 symptoms
Medication					
Fluoxetine ²⁸	Also sold as Prozac	Age 7–17 years	Duration 3 months	Follow-up none	Anxiety outcomes (Effect sizes) ↓ Primary diagnoses ↓ 4 of 8 symptoms
Fluoxetine ²⁹	Prozac	7–17 years	3 months	none	↓ 1 of 6 symptoms
Sertraline ³⁰	Zoloft	5–17 years	2¼ months	none	↓ 6 of 7 symptoms
Sertraline ³¹	Zoloft	7–17 years	3 months	none	↓ 2 of 2 symptoms (OR=3.9; g=0.45)

*Anxiety outcomes included two different sources, including at least one that was blinded; for prevention and psychosocial treatment studies, postintervention follow-up was 3 months or more. ↓ Outcome was statistically significant d = Cohen's d G = Group delivery
× Outcome was not statistically significant OR = Odds ratio g = Hedges' g

Attention-Deficit/Hyperactivity Disorder (ADHD) Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age/Grade	Duration	Follow-up	ADHD outcomes (Effect sizes)
Prevention – Targeted					
Incredible Years G ³²	Parent Training (PT)	3–4 years	3 months	3 months	↓ 1 of 1 symptom
Incredible Years + Literacy training G ³³⁻³⁴	PT	5–6 years	6½ months	4 months	↓ 1 of 1 symptom
Legacy for Children G ³⁵⁻³⁶	PT	Prenatal	3¼ years	2 years	↓ 1 of 1 symptom (OR=0.50)
SAFE Children G ³⁷⁻³⁸	PT + child tutoring	6 years	5 months	4¼ years	↓ 1 of 6 symptoms
Psychosocial Treatment					
Behavioural and Social Skills Class G ⁴²	Child behaviour therapy (BT) + social skills training (SST) + PT	5–12 years	1¼ months	3 months	↓ 1 of 2 symptoms
Child Social Skills and Parenting Group G ⁴³	Child BT + SST + PT	8–10 years	1¼ months	3–4 months	↓ 1 of 2 symptoms (d=0.76)
New Forest Parenting Programme ⁴⁰	PT	3–7 years	2¾ months	8¼ months	↓ 1 of 3 symptoms (d=0.25)
Parenting Group G ⁴¹	PT	5–18 years	3 months	1 year	↓ 1 of 5 symptoms
Strongest Families – Parenting the Active Child ²⁶	Self-directed PT	8–12 years	3 months	5 months	↓ ADHD diagnosis (OR=2.74)
Medication					
Methylphenidate ¹⁸⁵	Concerta	8–17 years	1¼ months	none	↓ 3 of 3 symptoms (d=0.23–0.52)
Methylphenidate ¹⁸⁶	Concerta	6–12 years	¾ month	none	↓ 3 of 3 symptoms
Systematic Reviews					
Medication					
Methylphenidate, dextroamphetamine and atomoxetine were effective in significantly reducing ADHD symptoms. All produced similar side effects. Cost-effectiveness analysis favoured methylphenidate and dextroamphetamine given that these medications were less expensive while being as effective as atomoxetine based on 64 RCTs. ⁴⁴					
Medication and Psychosocial Treatment					
Methylphenidate, alone or combined with psychosocial treatments, were significantly more effective than psychosocial treatments alone at end of treatment based on 26 RCTs. The effect sizes were largest for combined treatments (d=1.77–1.89) compared to medications alone (d=1.53–1.83) and psychosocial alone (d=0.75–0.87) based on parent and teacher ratings. ⁴⁵					
*ADHD prevention outcomes included one source while psychosocial treatment outcomes included two differences sources, including at least one that was blinded; for prevention and psychosocial treatment studies, postintervention follow-up was 3 months or more.					
G = Group delivery ↓ Outcome was statistically significant OR = Odds ratio d = Cohen's d					

Conduct and Oppositional Defiant Disorder Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age/Grade	Duration	Follow-up	Behaviour outcomes (Effect sizes)
Prevention – Universal					
Good Behavior Game G ⁶⁰	Child behaviour therapy (BT)	Grade 1	2 school years	14 years	↓ Antisocial personality diagnoses
Triple P G ⁴⁶⁻⁴⁷	Parent training (PT)	3-6 years	1 month	4 years	↓ 2 of 8 symptoms
Triple P G ⁴⁸⁻⁴⁹	PT	Grade 1	1 month	8 years	↓ 2 of 7 symptoms (d=0.11-0.15)
Prevention – Targeted					
Chicago Parent Program G ⁵⁰	PT	2-4 years	2¾ months	1 year	↓ 2 of 4 symptoms
Classroom-Centred Intervention G ⁶¹⁻⁶²	Child social skills training (SST), BT + enriched curricula	Grade 1	1 school year	5 years	↓ Conduct diagnoses (OR=0.42)
				5-11 years	↓ 1 of 1 symptom
Family School Partnership G ⁶¹⁻⁶²	PT + parent-school collaboration	Grade 1	1 school year	5 years	× Conduct diagnoses
				5-11 years	↓ 1 of 1 symptom
Fast Track G ⁶³⁻⁶⁴	PT, child SST+ tutoring	Grade 1	10 school years	8 years	↓ Antisocial personality diagnoses (OR=0.60) ↓ 2 of 5 symptoms
Incredible Years Basic G ⁵¹	PT	3-4 years	2¾ months	3¼ months	↓ 2 of 4 symptoms (d=0.63-0.89)
Incredible Years Enhanced G ⁵²	PT	2-5 years	9-11 months	8 months	↓ 1 of 2 symptoms
Nurse Family Partnership ⁵³	PT	Prenatal	2¼ years	13 years	↓ 3 of 14 symptoms
Parent-Management Training – Oregon G ⁵⁴	PT	6-10 years	3¼ months	8¾ years	↓ 3 of 3 symptoms (d=0.28)
Perry Preschool G ⁶⁵	Parent school collaboration + enriched curricula	3-4 years	1¼ years	35 years	↓ 2 of 9 symptoms (OR=0.48-0.54)
Strongest Families Smart Website ⁵⁵⁻⁵⁶	Self-directed PT with coaching	4 years	10 months	1¼ years	↓ 1 of 2 symptoms (d=0.22)
Triple P Online ⁵⁷	Self-directed PT with coaching	2-8 years	4 months	5 months	↓ 2 of 3 symptoms (d=0.70-1.28)
Triple P Online Brief ⁵⁸	Self-directed PT	2-9 years	2 months	9 months	↓ 2 of 4 symptoms (d=0.39-0.41)
Psychosocial Treatment					
Brief Intervention ⁶⁹	Child cognitive-behavioural therapy (CBT)	11-17 years	½ month	2 years	↓ 1 of 1 symptom
Incredible Years Basic G ⁶⁶⁻⁶⁷	PT	3-7 years	3-3¾ months	7¾ years	↓ Oppositional defiant diagnoses (OR=0.20) ↓ 1 of 3 symptoms
Multidimensional Treatment Foster Care G ⁷⁰⁻⁷¹	PT + child SST	12-17 years	6¾ months	1½ years	↓ 2 of 2 symptoms
Multidimensional Treatment Foster Care G ⁷²	PT+ child SST	13-17 years	5¾ months	1½ years	↓ 1 of 3 symptoms
Multisystemic Therapy ♂ ⁷³	PT + child CBT	11-17 years	7 months	1½ years	↓ 1 of 2 symptoms (OR=0.41)
Parent-Child Interaction Therapy ⁶⁸	PT	2-7 years	5 months	1 year	↓ 2 of 5 symptoms (d=0.61-0.64)
Medication					
Risperidone ⁷⁴	Risperdal	12-18 years	1½ months	none	↓ 1 of 3 symptoms
Risperidone ⁷⁵	Risperdal	6-14 years	2½ months	none	↓ 5 of 6 symptoms
Risperidone ⁷⁶	Risperdal	5-12 years	1½ months	none	↓ 3 of 3 symptoms

*Behaviour outcomes included two different sources, including at least one that was blinded; for prevention and psychosocial treatment studies, postintervention follow-up was 3 months or more. G = Group delivery ↓ Outcome was statistically significant d = Cohen's d OR = Odds ratio × Outcome was not statistically significant ♂ = Boys only ♀ = Girls only

Substance Use Disorder Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age/Grade	Duration	Follow-up	Substance use outcomes (Effect sizes)
Prevention – Universal					
Iowa Strengthening Families G ⁷⁷	Parent training (PT) + child resistance skills	Grade 6	1½ months	9 years	↓ 2 of 4 symptoms (RRR=19%-21%)
Life Skills Training G ⁷⁸⁻⁷⁹	Child social skill training (SST) + resistance skills	Grade 7	1¾ school years	1 year	↓ 2 of 5 symptoms
Preparing for the Drug Free Years G ^{77, 80}	PT + child resistance skills	Grade 6	1¼ months	9-10 years	↓ 1 of 5 symptoms (RRR=11%)
Project PATHS G ⁸¹⁻⁸³	Child communication skills + SST	Grades 7-9	3 school years	2 years	↓ 6 of 7 symptoms
Substance Use Prevention for Girls G ⁸⁴	Self-directed child communication skills + resistance skills + PT	11-13 years	2¼ months	1 year	↓ 3 of 3 symptoms
Unplugged G ⁸⁵	Child education + resistance skills	Junior high schoolers	2¾ months	1¼ years	↓ 2 of 4 symptoms (OR=0.62-0.80)
Unplugged G ⁸⁶	Child education + resistance skills	Grade 6	1 school year	2 years	↓ 1 of 5 symptoms (OR=0.56)
Prevention – Targeted					
CHAT ⁹⁰	Child motivational interviewing (MI)	12-18 years	15 minutes	1 year	↓ 2 of 7 symptoms
Middle School Success G ♀ ⁸⁸	Child SST + coaching + caregiver training	10-12 years	1 year	2 years	↓ 1 of 2 symptoms (d=0.57)
Preventure G ⁹¹⁻⁹²	Child education, MI + cognitive-behavioural therapy (CBT)	Grades 8-10	½ month	2 years	↓ 3 of 5 symptoms (d=0.18-0.25)
Preventure G ⁹³⁻⁹⁴	Child education, MI + CBT	Grade 8	½ month	2 years	↓ 3 of 6 symptoms (OR=0.71)
Psychosocial Treatment					
Adolescent Cannabis Check-Up ⁹⁶	Child MI + CBT	14-19 years	½ month	3 months	↓ 3 of 3 symptoms (d=0.22-0.71)
Brief Intervention ⁹⁷	Child MI	Grade 9-12	½ month	6 months	↓ 4 of 5 symptoms
	Child MI + PT	Grade 9-12	¾ month	6 months	↓ 2 of 5 symptoms
Integrated Family + Cognitive-Behavioural Therapy G ⁹⁸	Family communication skills, PT + child CBT	14-18 years	3¾ months	6 months	↓ 2 of 3 symptoms
Multidimensional Family Therapy ⁹⁹	Family communication skills, PT + Child SST	13-18 years	6 months	6 months	↓ 1 of 3 symptoms (d=1.66)
Multidimensional Family Therapy ¹⁰⁰	Family communication skills, PT + Child SST	12-17 years	4-6 months	1 year	↓ 3 of 6 symptoms (d=0.32-0.59)
Multidimensional Family Therapy ¹⁰¹	Family communication skills, PT + Child SST	11-15 years	3-4 months	8¼ months	↓ 3 of 5 symptoms (d=0.77-1.36; OR=2.20)
*SUD outcomes included one source; for prevention studies, postintervention follow-up was 1 year or more; for treatment studies, postintervention follow-up was 3 months or more; for universal prevention programs, all interventions were delivered in schools. G = Group delivery ↓ Outcome was statistically significant RRR = Relative risk reduction ♀ = Girls only OR = Odds ratio d = Cohen's d					

Depression Evidence*						
Randomized Controlled Trials						
Program	Program elements	Age/Grade	Duration	Follow-up	Mood outcomes (Effect sizes)	
Prevention – Targeted						
Coping with Stress G ¹⁰²	Child cognitive-behavioural therapy (CBT)	Grades 9-10	1¼ months	1 year	↓ depression/dysthymia diagnoses × 4 of 4 symptoms	
Coping with Stress G ¹⁰³	Child CBT + parent education	13-18 years	3½ months	2 years	× depression diagnoses ↓ 4 of 6 symptoms	
Coping with Stress G ¹⁰⁴	Child CBT	14-19 years	1½ months	4½ months	↓ depression diagnoses (OR=2.5) ↓ 2 of 2 symptoms (d=0.39-0.42)	
Coping with Stress G ¹⁰⁵⁻¹⁰⁶	Child CBT	13-19 years	1½ months	2 years	↓ depression diagnoses (HR=2.48)	
Family Group CBT G ¹⁰⁷	Family CBT	9-15 years	2¾ months	1½ years	↓ depression diagnoses (OR=2.91) × 1 of 1 symptom	
Feeling Good ¹⁰⁴	CBT book	14-19 years	1½ months	4½ months	↓ depression diagnoses (OR=4.5) ↓ 1 of 2 symptoms (d=0.28)	
Icelandic Prevention G ¹⁰⁸	Child CBT	14-15 years	2½ months	1 year	↓ depression/dysthymia diagnoses (HR=0.18)	
Systematic Review						
Psychosocial Treatment						
Interpersonal Therapy (IPT) and CBT were the only psychotherapies among the nine assessed that were significantly more effective than most comparison conditions at the end of treatment and follow-up based on 52 RCTs. IPT produced slightly larger effect sizes than CBT at both end of treatment and at follow-up (IPT Surface under the cumulative ranking curve at post-test=90.5%; at follow-up=90.3%). ¹¹⁰						
Randomized Controlled Trials						
Medication	Also sold as	Age	Duration	Follow-up	Mood outcomes (Effect sizes)	
Fluoxetine ¹¹²	Prozac	12-17 years	2¾ months	none	↓ 3 of 7 symptoms	
Fluoxetine ¹¹³	Prozac	7-17 years	1¾ months	none	↓ 2 of 4 symptoms	
Fluoxetine ¹¹⁴	Prozac	8-17 years	2 months	none	↓ 4 of 5 symptoms (d=0.31-0.54)	
Fluoxetine ¹¹⁵	Prozac	13-19 years	3¾ months	none	↓ 1 of 2 symptoms (g=0.78)	
*Mood outcomes included two different sources, including at least one that was blinded; for prevention and psychosocial treatment studies, postintervention follow-up was 3 months or more and included diagnostic outcomes. G = Group delivery ↓ Outcome was statistically significant × Outcome was not statistically significant OR = Odds ratio d = Cohen's d HR = Hazard ratio g = Hedges' g						

Autism Spectrum Disorder Evidence	
Systematic Review	
Psychosocial Treatment	
Behavioural and cognitive-behavioural interventions with preschool and school-age children produced improvements in communication, socialization and adaptive behaviour based on eight RCTs contained in a systematic review (SR). Five behavioural programs taught parents strategies to encourage their children's social interactions. The remaining three programs taught children social skills in groups or using a computer program. ¹¹⁷	

Obsessive-Compulsive Disorder (OCD) Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age	Duration	Follow-up	OCD outcomes (Effect size)
Psychosocial Treatment					
Cognitive-Behavioural Therapy (CBT) ¹²⁶	Child CBT	9-18 years	3 months	none	↓ 1 of 2 symptoms ($d=1.07$)
CBT ¹²⁷	Child CBT	10-18 years	3 months	none	↓ OCD diagnosis ↓ 4 of 4 symptoms ($d=1.6-2.2$)
CBT + Positive Family Interaction Therapy † ¹³⁴	Child CBT + family education + problem-solving	8-17 years	2¾ months	none	↓ 2 of 3 symptoms ($\phi=0.28$)
Family-based CBT ¹²⁹	Family CBT	3-8 years	1½ months	none	↓ 5 of 5 symptoms ($d=1.24-1.69$)
Family-based CBT ¹³⁰	Family CBT	5-8 years	3¼ months	none	↓ 3 of 4 symptoms ($d=0.31-0.84$)
Family-based CBT ¹³²	Family CBT	8-17 years	3¼ months	none	↓ 1 of 4 symptoms
Internet-Delivered Family CBT ¹³¹	Family CBT	7-16 years	2¾ months	none	↓ 5 of 5 symptoms ($\eta^2=0.16-0.44$)
Internet-Delivered Family CBT ¹³³	Self-directed family CBT with coaching	12-17 years	2¾ months	none	↓ 6 of 7 symptoms ($d=0.69$)
Telephone-Delivered CBT** ¹²⁸	Child CBT	11-18 years	4 months	1 year	↓ 2 of 3 symptoms
Systematic Review					
Psychosocial Treatment and Medication					
CBT produced significantly larger treatment effects ($d = 1.45$) than the medications fluoxetine, sertraline, paroxetine and clomipramine (average $d = 0.48$) based on 13 RCTs, of which 5 evaluated CBT. Among the medications, fluoxetine and sertraline had moderate effect sizes ($d = 0.51$ and 0.47) and the most favourable adverse event profiles. ¹³⁶					
*OCD outcomes included two different sources, included at least one that was blinded ↓ Outcome was statistically significant $d =$ Cohen's d † Limited to children from families with 2+ indicators of poor family functioning associated with diminished response to CBT. $\phi =$ Phi $\eta^2 =$ Eta squared **A non-inferiority trial designed to evaluate if CBT delivered by telephone was as effective as CBT delivered in-person.					

Bipolar Evidence*					
Randomized Control Trials					
Program	Program elements	Age	Duration	Follow-up	Bipolar outcomes (Effect size)
Psychosocial Treatment**					
Child- and Family-Focused Cognitive-Behavioural Therapy (CBT) ¹³⁹	Family education, problem-solving, communication skills + CBT	7-13 years	9 months	none	↓ 2 of 5 symptoms† (d=0.48-0.50)
Family-Focused Therapy ¹⁴⁰	Family education, problem-solving, + communication skills	12-17 years	9 months	1¼ years	↓ 1 of 2 symptoms†
Family-Focused Therapy ¹⁴¹	Family education, problem-solving, + communication skills	9-17 years	4 months	8 months	↓ 1 of 2 symptoms (d=0.49)
Multifamily Psychoeducational Psychotherapy G ¹³⁸	Family education problem-solving, + communication skills	8-11 years	1¾ months	10 months	↓ 1 of 1 symptom
Medication					
Medication	Also sold as	Ages	Duration	Follow-up	Bipolar outcomes (Effect size)
Lithium ¹⁴²	Carbolith	12-18 years	1½ months	none	↓ 1 of 2 symptoms†
Lithium ¹⁴³	Carbolith	7-17 years	1¾ months	none	↓ 2 of 5 symptoms (d=0.53)
*Bipolar outcomes included at least one blinded measure; outcomes included manic or hypomanic symptoms; studies with insufficient statistical power or inappropriate analyses were excluded. ** Psychosocial treatments were adjunctive to medications in most cases ↓ Outcome was statistically significant † None of the significant outcomes included reductions in manic or hypomanic symptoms. d = Cohen's d G = Group delivery					

Eating Disorders Evidence*					
Randomized Control Trials					
Program	Program elements	Age/Grade	Duration	Follow-up	Eating disorder outcomes (Effect size)
Prevention – Universal					
Education Program G ♀ ¹⁴⁴	Media literacy training, discouraging unhealthy weight control practices + encouraging positive body image	Grades 11-12	1½ months	10 months	× Anorexia diagnoses ↓ Bulimia diagnoses ↓ 2 of 5 symptoms
Prevention – Targeted					
Dissonance G ♀ ¹⁴⁵⁻¹⁴⁶	Discouraging unhealthy weight control practices + encouraging positive body image	14-19 years	3 weeks	3 years	↓ 3 of 6 symptoms (d=0.19-0.43; HR=2.50)
Dissonance G ♀ ¹⁴⁷⁻¹⁴⁸	Discouraging unhealthy weight control practices + encouraging positive body image	14-19 years	1 month	3 years	× Eating disorder diagnoses ↓ 1 of 5 symptoms (d=0.30)
Healthy Weight G ♀ ¹⁴⁹	Discouraging unhealthy weight control practices + implementing healthy lifestyle plan	14-19 years	3 weeks	1 year	↓ 3 of 4 symptoms
Healthy Weight G ♀ ¹⁴⁵⁻¹⁴⁶	Discouraging unhealthy weight control practices + implementing healthy lifestyle plan	14-19 years	3 weeks	3 years	↓ 5 of 6 symptoms (d=0.08-0.28; HR=2.27-2.75)
Student Bodies ¹⁵⁰	Self-directed media literacy training, discouraging unhealthy weight control practices + encouraging positive body image	14-18 years	3¼ months	5 months	↓ 2 of 4 symptoms
Systematic Review					
Psychosocial Treatments					
Family therapy resulted in significantly more young people achieving remission from anorexia nervosa at follow-up (ranging from 6-12 months) than individual therapy despite no group difference at end of treatment based on 3 RCTs. Family therapy similarly resulted in significantly more young people achieving remission from bulimia nervosa at follow-up (ranging from 6-12 months) than individual therapy despite no group difference at end of treatment based on 2 RCTs. ¹⁵¹					
*Eating disorder prevention outcomes included two different sources, including at least one that was blinded; For prevention studies, postintervention follow-up was 3 months or more. G = Group delivery ♀ = Girls only × Outcome was not statistically significant ↓ Outcome was statistically significant d = Cohen's d HR = Hazard ratio					

Posttraumatic Stress Disorder (PTSD) Evidence*					
Randomized Controlled Trials					
Program	Program elements	Age	Duration	Follow-up	PTSD outcomes (Effect size)
Prevention – Targeted					
Fostering Healthy Futures G ¹⁵⁵⁻¹⁵⁶	Child cognitive-behavioural therapy (CBT) + mentoring	9-11 years	9 months	6 months	↓ 2 of 3 symptoms (d=0.39-0.51)
Fostering Healthy Futures G ¹⁵⁷	CBT + mentoring	9-11 years	9 months	6 months	↓ 3 of 3 symptoms (d=0.20-0.29)
It's My Turn Now G ¹⁵⁸	Child CBT + Parent Training (PT)	6-12 years	2¼ months	6 months	↓ 1 of 2 symptoms
Multisystemic Therapy ¹⁵⁹	Child CBT + PT	10-17 years	8 months	4 months	↓ 3 of 6 symptoms (d=0.55-0.73)
Risk Reduction through Family Therapy ¹⁶⁰	Child CBT + family problem-solving	13-17 years	7¼ months	6 months	↓ 1 of 2 symptoms
Psychosocial Treatment					
KIDNET G ¹⁶³	Child CBT	7-16 years	1¾ months	4¼ months	↓ 4 of 5 symptoms
Prolonged Exposure Therapy ¹⁶¹	Child CBT	12-18 years	3½ months	6 months	↓ 2 of 2 symptoms (d=0.51-0.55)
Prolonged Exposure Therapy ♀ ¹⁶²	Child CBT	13-18 years	3¼ months	1 year	↓ PTSD diagnoses ↓ 3 of 3 symptoms (d=0.81)

*PTSD outcomes included two different sources, included at least one that was blinded for treatment studies; postintervention follow-up was 3 months or more. G = Group delivery ↓ Outcome was statistically significant d = Cohen's d ♀ = Girls only

Schizophrenia Evidence*					
Randomized Control Trials					
Medication	Also sold as	Age	Duration	Follow-up	Psychosis outcomes (Effect size)
Aripiprazole ¹⁶⁴	Abilify	13-17 years	1½ months	none	↓ 6 of 7 symptoms
Aripiprazole (vs quetiapine) ¹⁶⁵	Abilify	12-17 years	2¾ months	none	↓ 1 of 1 symptom**
Olanzapine ¹⁶⁶	Zyprexa	13-17-years	1½ months	none	↓ 5 of 6 symptoms
Olanzapine (vs clozapine) ¹⁶⁷	Zyprexa	7-16 years	1¾ months	none	↓ 3 of 5 symptoms** (d=0.6-1.3)

*Schizophrenia outcomes included at least one blinded measure; head-to-head trials were accepted if at least one medication was already established as being effective in a placebo-controlled RCT with young people; studies with insufficient statistical power or inappropriate analyses were excluded. ↓ Outcome was statistically significant ** For head-to-head trials, reported outcomes are time effects. d = Cohen's d